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The streptococcal collagen-like protein-1 (Scl1) is a multifunctional adhesin 
in extracellular matrix interactions, biofilm formation, and host colonization 
by group A Streptococcus  
 
Heaven A. Oliver-Kozup 
Group A Streptococcus (GAS) is responsible for over 100 million skin infections 
annually that may lead to invasive episodes and autoimmune sequelaes. 
Wounds and unapparent skin infringements are susceptible to the introduction of 
GAS and serve as a portal of entry. The nutritional nature of a wound and the 
accessibility to exposed host cell surfaces and extracellular matrix components  
create a model milieu for successful host colonization and potential biofilm 
formation. The initiation of biofilm is often mediated by bacterial surface adhesins 
and has been shown to interfere with wound healing by blocking critical host 
cellular interactions. However, the underlying molecular mechanisms supporting 
this impediment of wound healing are not completely understood. Here, we 
characterize the GAS surface adhesin, streptococcal collagen-like protein-1 
(Scl1), and its interaction with extracellular matrix components and contribution to 
GAS biofilm formation. Scl1 has been detected in all GAS strains and extends 
from the GAS surface as a homotrimeric protein composed of a collagen-like 
domain, structurally similar to mammalian collagen, and an adjacent amino-
terminal non-collagenous variable domain. The current work (i) identifies that the 
Scl1 variable domain binds to extracellular matrix proteins, cellular fibronectin 
and laminin and contributes to GAS adherence and internalization (ii) 
demonstrates that the Scl1 protein is an important determinant of GAS biofilm 
formation on untreated and ECM-deposited surfaces, and (iii) characterizes a 
novel molecular mechanism by which GAS utilizes the Scl1 protein to specifically 
target the EDA-containing variant of cellular fibronectin predominantly expressed 
at the site of injured tissue in order to secure host colonization and biofilm 
formation. In total, these studies further demonstrate the importance of the Scl1 
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Overview of Group A Streptococcus. Streptococcus pyogenes comprises the 
single group within the Lancefield classification scheme known as group A 
Streptococcus (GAS), which is based on serologic typing of the cell surface 
carbohydrate. Strains have been further subtyped based on the surface-
expressed M-protein (21). GAS is a gram-positive, adaptive, exclusive human 
pathogen that causes a wide spectrum of diseases but can also reside 
undetected among asymptomatic human carriers (75), with a rate that can 
exceed 20 percent in school-age populations. GAS commonly causes throat and 
skin infections. Suppurative, non-invasive diseases such as pharyngitis and 
pyoderma make up 75 percent of global GAS cases. GAS is also responsible for 
severe, life-threatening, invasive diseases such as necrotizing fasciitis and 
streptococcal toxic-shock syndrome (82, 111, 112, 123). Mounting post-
streptococcal diseases account for 11 percent of global GAS-associated cases. 
Rheumatic heart disease (RHD) and acute glomerulonephritis (AGN) are among 
these sequelae (42). In addition, research in recent years has linked GAS 
infections with a range of neurological conditions in children collectively referred 
to as ‘pediatric autoimmune neuropsychiatric disorders associated with 
streptococcal infections’ (PANDAS) (7, 69, 74). On a positive note, extensive 
genetic and molecular research on GAS is unyielding, living conditions and 
nutrition are improving in third-world countries with GAS epidemics, treatment of 
GAS infections is advancing due to better diagnostic tools, and surveillance and 
reports of outbreaks occurring are broadening worldwide. However, much is yet 
to be discovered about the interactions of GAS with the human host. 
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GAS Epidemiology and Global Burden. Epidemiology of GAS has 
progressively changed over the last two hundred years with the improvements in 
nutritional and environmental conditions contributing. Historically, epidemics have 
been documented in Europe during early nineteenth and twentieth centuries 
regarding infections that would resemble current clinical manifestations such as 
scarlet fever. The continued global prevalence of GAS results in increasing cases 
of throat and skin diseases, specifically in less developed countries. In the United 
States, there are 25-35 million cases of GAS suppurative, non-invasive throat 
and skin infections such as pyoderma and pharyngitis per year, resulting in a 
financial burden of up to 2 billion dollars annually. Global estimates of throat and 
skin infections reach above 600 million total cases of GAS infections each year 
(10). Life-threatening, invasive infections and non-suppurative sequelae account 
for more than 18 million cases globally, increasing by almost 2 million each year. 
The mortality rate from acquisition of these diseases is approaching 3 percent or 
520,000 annually (75, 78). Supporting this degree of prevalence, GAS expresses 
numerous virulence factors that contribute to its role as a successful human 
pathogen. 
GAS Pathogenesis Strategies and Virulence Factors. Over the last 
decade, molecular pathogenomics has facilitated and heightened our 
understanding of genetics and molecular mechanisms contributing to GAS 
pathogenesis. This broadened spectrum of knowledge allows us to anticipate 
prospective GAS infections resulting from clone-emergence or previous strain 
reemergence appearing as an altered clinical phenotype. Coordination of 
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secreted and surface expressed virulence factors provides a well-tuned arsenal 
for host colonization and immune evasion that is reliant upon environmental and 
growth conditions, phase of growth of the bacterium but also the immune 
response and genetic predisposition of the host (75). Virulence factors include 
the cell surface-expressed proteins such as the M protein and streptococcal 
collagen-like proteins, hyaluronic acid capsule, pili, extracellular matrix binding 
proteins, proteinases, DNases, and streptokinases. Numerous superantigens 
have been identified in the GAS genome with several located on mobile DNA 
elements and bacteriophages (93). Expression profiles of these virulence factors 
are strain-specific which also produces variations in pathogenesis strategies and 
disease capacity (17, 120). Many genes encoding these virulence factors are 
located within the mga regulon. Mga, the multigene activator, encoded by the 
mga gene coordinates the expression of some of these factors, which specifically 
includes the M protein, in response to environmental stresses and phases of 
growth (3). 
The M-protein is the most abundant fibrillar coiled-coil homodimeric 
protein appearing as hair-like projections extending from the cell wall. Serological 
M typing exploiting the hypervariable amino-terminal region of the protein, which 
displays extensive antigenic heterogeneity, was used historically to distinguish M 
serotypes (31, 42). This method was replaced with a nucleotide sequence-based 
typing scheme, which resulted in the identity of more than 200 types now listed 
online (http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm). Based on the 
number and arrangement of the emm and emm-like genes, there are five 
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conclusive patterns: A-C, D, and E. These patterns serve as reliable, genetic 
biomarkers for tissue tropism with pattern A-C genotypes showing a strong 
preference toward throat infections and pattern D genotypes having a 
predilection for skin infections (4, 5, 57).  
GAS Treatment and Vaccine Development Strategies. In the pre-
antibiotic era, GAS infections were very common and responsible for almost half 
of post-partum deaths as well as being the main bacterium associated with burn 
victims (29). After the introduction of penicillin, reports of GAS disease had 
dramatically declined by the 1970s. However, by the 1990s, resurgence in not 
only superficial infections but also post-streptococcal sequelae surfaced around 
the globe (29).     
The study of GAS’s antigenic variation and mechanisms of immune 
evasion aid in the development of an efficacious vaccine that addresses both 
superficial and invasive infections. Potential vaccine candidates most often 
include conserved cell-surface proteins associated with multiple GAS strains 
such as the C5a peptidase (ScpA) which proved to be successful in reducing 
GAS colonization within a rabbit pharyngitis model (16, 48). Other investigations 
have identified a number of other vaccine candidates including fibronectin 
binding proteins, F1 and FBP54 (19, 37, 52) as well as the group A carbohydrate 
(136). Unfortunately, efficacy and degree of protection have not been established 
for these proteins. The development of a multivalent vaccine containing the 
amino-terminal peptides of M proteins from twenty-six epidemiologically 
important M-types (68) was completed; however, clinical trials were only in part 
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successful in disease inhibition after challenge. Because the majority of GAS 
infections occur within the mucosal membrane of the nasopharynx, several 
mucosally-active vaccines, including virus-like particle (VLP) approaches and 
lipopeptide delivery systems, have been developed which incorporate antigenic 
peptides derived from the M-protein. Success has been only partial in mouse 
models. Many disadvantages prevail in developing a universal vaccine for GAS 
diseases including antigenic variation among the same serotype, cross-reactivity 
between GAS and human antigens resulting in autoimmune sequelae, and the 
geographic distribution of strains (43, 100, 110, 137, 138). Collective efforts are 
ongoing to develop an efficacious, non-toxic, cheap, and easily distributable 
vaccine for GAS.  
GAS Interaction with Extracellular Matrix.  Bacterial adherence within 
host tissues is the first and most crucial step in colonization within a host point of 
entry and mediated by surface adhesins. Many ‘microbial surface components 
recognizing adhesive matrix molecules’ (MSCRAMMs) have been identified for 
GAS and characterized based on their interaction with eukaryotic cell surface 
components and extracellular matrix components such as collagen, laminin, 
fibrinogen and elastin. Among the more reported interaction is the binding to 
fibronectin (Fn). The fibronectins, plasma (soluble) and cellular (insoluble) forms, 
comprise of large family of glycoproteins that are biologically important in cellular 
interactions of the extracellular matrix including matrix assembly and 
restructuring, cell migration, and cell differentiation (87). Fn is a common target 
for GAS and is used as a “bridging mechanism” for adhesion and internalization 
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into epithelial and endothelial cells. The expression profile of these Fn-binding 
adhesins on the GAS surface varies among the M-types and often provides 
information toward tissue specificity and type as well as the potential severity of 
GAS pathogenesis (130). More than eleven Fn-binding proteins have been 
identified to date that can be grouped into two major categories: those containing 
Fn-binding repeats and those lacking them. Table 1 lists the reported GAS Fn-
binding proteins, including their Fn-binding site (if available) and the resulting 
function (if known). Of these proteins, the most extensively studied in vitro is the 
F1 (PrtF1/SfbI) protein. The importance of this protein in GAS pathogenesis has 
been widely supported with most of these studies finding a correlation between 
F1 expression, Fn-binding, and epithelial cell adhesion, internalization, and 
evasion of phagocytosis (41, 47, 58, 72, 83, 105, 106, 116-118). F1 is one of 
seven GAS proteins possessing Fn-binding repeats that interact with the N-
terminus of Fn, which includes type I repeats 1-5, the heparin binding site. F1 
also contains a region, located upstream of Fn-binding repeats, interacting with 
type I repeats 8 and 9, constituting the gelatin/collagen binding site. The Fn-
binding repeats are found in Fn-binding proteins of many other bacteria, including 
proteins FnbpA and B of Staphylococcus aureus. Upon binding to Fn, they form a 
“tandem -zipper which facilitates bacterial internalization via Fn-bridging (130). It 
should be noted that these Fn-binding proteins recognize and bind the N-terminal 
region of the molecule, which is common in both the plasma (pFn) and cellular 
(cFn) forms of Fn. In this work, I will describe and characterize a novel selective 
cFn-binding mechanism, which is unique to the Scl1 protein. 
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Final Remarks. Over the last century, enormous strides have been taken 
to understand the pathogenesis of GAS. As detailed in the previous sections, 
GAS is a dynamic, highly adaptable, and often injurious human pathogen 
maintaining numerous virulence factors allowing for host immune evasion, tissue 
colonization, and disease progression. Efforts continue to unravel pathogenesis 
mechanisms involving GAS surface adhesins. One such adhesin is the 
streptococcal collagen-like protein-1 (Scl1) which over the last decade has been 
characterized as an important pathogenicity factor interacting with human plasma 
components and eukaryotic cell surface receptors. The following sections within 
this Chapter provide a synopsis of the Scl proteins with the subsequent Chapters 




Table 1. Group A Streptococcus Fibronectin Binging Proteins 
Fn-Binding Protein Fn-Binding 
Motif 
   Binding Function References 
    





Talay et al, 1992, 1994, 2000; 
Ozeri et al 1996, 1998; 
Hanski and Caparon, 1992; 
Molinari et al 1997; 
Kreikemeyer et al, 2004; 
Schwartz-Linck et al 2004, 
2006; Hyland et al, 2007 
F2 (PrtF2)/PFBP HBD Adhesion Jaffe et al, 1996; Rocha and 
Fischetti, 1999; Kreikemeyer 
et al, 2004 
FbaA ? Adhesion Terao et al, 2001 Kawabata 
et al, 2001 
FbaB ? Adhesion, 
internalization 
Terao et al, 2002; Amelung et 
al, 2011 
SOF/SfbII HBD Adhesion Rakonjac et al, 1995; 
Courtney et al, 1999; Jeng et 
al, 2003; Oehmcke et al, 
2004 
FBP54 HBD Adhesion Courtney et al, 1994, 1996 
M protein HBD Adhesion, 
internalization, evasion 
of phagocytosis 
Cue et al, 1998, 2001; 
Molinari and Chhatwal, 1999 
GADPH (glyceraldehydes- 
3-phosphate dehydrogenase 
? Adhesion Pancholi  and Fischetti, 1992 
Protein H Fn type III Adhesion Frick et al, 1995 
SfbX HBD adhesion Jeng et al, 2003 
SHR ? Adhesion Fisher et al, 2008 




Caswell et al, 2010; Oliver-
Kozup et al, 2012 
    
HBD: heparin-binding domain Fn type I (1-5 repeats); GBD: gelatin/collagen binding domain Fn 





Streptococcal Collagen-like Proteins. Collagens comprise a ubiquitous and 
indispensible family of proteins that are the primary constituents contributing to 
the assembly and stabilization of the extracellular matrix of animals. The 
structural hallmark of collagens is its triple helical nature derived from three left-
handed, polyproline II-type chains forming a right-handed superhelix (71, 94). 
With at least twenty-eight types of mammalian collagen identified, its importance 
in cellular development and the capacity for binding to multiple matrix 
components, it is no surprise that pathogenic bacteria have developed surface 
proteins to bind collagen or structurally and functionally mimic collagen (58). 
Spanning now more than a decade, the identification of collagen-like sequences 
in prokaryotes and bacteriophages has expanded (97) and characterization of 
the structural stabilization and biological function has continued with much 
information gained by studies with the streptococcal collagen-like (Scl) proteins 
of GAS (40, 128). 
Scl Genes and Protein Expression. GAS expresses two cell surface-
anchored proteins encoded by the scl1 and scl2 genes, also referred to as sclA 
and sclB, respectively (63, 96, 126). The scl1 and scl2 genes are located on 
opposite sites of the GAS chromosome and their expression is controlled by 
different mechanisms. The expression of scl1 is regulated at the level of 
transcription by the positive multiple gene regulator, Mga, similarly to several 
known GAS virulence factors within the Mga regulon. In contrast, control of 
expression of the Scl2 resides at the level of translation and depends on the 
number of CAAAA pentanucleotide repeats found downstream to a GTG start 
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codon. Based on the number of these repeats, the scl2-coding sequence may be 
in-frame, resulting in expression of the full-length protein, or out-of-frame, leading 
to early translation termination (64, 95). 
Scl Protein Structure. The Scl1 and Scl2 proteins are structurally similar 
and contain an amino-terminal signal sequence (SS) commonly found in 
extracellular proteins (Figure 1). The cell wall-membrane associated region (WM) 
contains a conserved cell-wall anchor LPXTG motif. A linker (L) region, only 
found in Scl1, connects the WM with the collagen-like (CL) region and is 
composed of a series of conserved direct PGEKAPEKS repeats. The CL region 
of the Scl protein extends from the cell surface and is composed of a series of 
GXY repeats, where G is glycine and X and Y are other amino acids. The CL 
regions vary in length among Scl variants due to the different numbers of GXY 
repeats and form stable triple helices under physiological conditions. The amino 
terminal portion of the mature Scl proteins, designated the variable (V) region, 
also varies in length and primary sequence among Scl variants. Secondary 
structure predictions support that the V region is composed of two alpha-helices 
and may be amphipathic in nature with a probability towards forming a coiled-coil 
structure. As shown by electron microscopy of rotary-shadowed Scl proteins, a 
“lolli-pop”-like structural organization of the homotrimeric Scl molecules is formed 
with the CL region making up a stalk of varying lengths depending on the variant 



















Figure 1. Structure and domain organization of Scl1.  Top: Cartoon model of 
the Scl1 protein (not to scale). Three polypeptide chains are shown in blue, red, 
and yellow. Four arbitrarily designated regions and the range of amino-acid (aa) 
length are shown: V, variable region; CL, collagen-like region; L, linker region, 
and WM, cell wall-membrane associated region . Bottom: Electron microscopy of 
rotary shadowed recombinant Scl1 proteins shows a “lolli-pop”-like structural 
organization with the V region forming a globular head and the CL region forming 
the stalk. Scale bar represents 50 nanometers. Images within this figure are used 
with permission by Slawomir Lukomski. 
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Stabilization of Scl Proteins. Stabilization of mammalian collagens 
results from the unique high content of hydroxyproline residues. Post-
translational modification by prolyl hydroxylase of proline residues constituting 
the Y position within the GXY sequence serves as a stabilizing measure to 
preserve the triple helical confirmation (8, 9). Most information known about the 
triple-helix stabilization of prokaryotic collagen-like proteins is from the 
characterization of the Scl proteins of S. pyogenes (40) (71); however, multiple 
other prokaryotes such as Bacillus cereus (122), Bacillus anthracis (115), 
Pneumococcus (88), Clostridium (97, 127, 134), Streptococcus equi (51), and 
many others possess similarly structured surface proteins. Due to the lack of 
prolyl hydroxylase, prokaryotes are restricted to alternative mechanisms to 
stabilize the triple helix of the CL region (127). In the first assessment of Scl 
proteins for the formation of a stable triple-helical CL domain, Xu and co-workers 
generated recombinant Scl1 and Scl2 proteins from M1- and M28-type GAS 
strains, respectively. Trypsin digestion was performed to test the susceptibility of 
the recombinant Scl proteins to proteolytic digestion. Similar to mammalian 
collagens, they were relatively resistant to proteolysis suggesting the presence of 
a stable, collagen-like structure. Furthermore, circular dichroism spectroscopy 
showed a molar ellipticity maximum () for these recombinant proteins around 
220 nm, which is a characteristic of a collagen triple-helix structure. Thermal 
stability studies revealed a mid-melting temperature (Tm) range for these proteins 
between 32-39 oC with an increased Tm for proteins containing longer CL 
domains (128). Using knowledge gained from previous biophysical experiments 
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and crystallographic models where stable collagen-like triple helices were formed 
with substitutions of certain amino acids in the proline and hydroxyproline 
positions, the authors proposed mechanisms that may participate in prokaryotic 
triple-helix stabilization. Such mechanisms include (i) the high content of charged 
amino acids with extended side chains, such as lysine and arginine that may 
directly interact with adjacent polypeptides; (ii) the presence of GXY triplets such 
as GPR, GER, GPA, GDR, GKD, and GEK previously been shown to stabilize 
the triple-helical structure; and importantly, (iii) the requirement of the V region for 
the trimerization and proper folding of the CL region (40, 128, 132, 133). 
 Function of the Scl Proteins. Since no known domains could be predicted 
for group A streptococcal proteins Scl1 and Scl2 with bioinformatic tools, their 
ligands were identified using experimental approaches. Thus, different Scl 
variants bind human extracellular matrix proteins cellular fibronectin and laminin, 
collagen integrin receptors 21 and 111, and plasma components including the 
low-density lipoprotein, thrombin-activatable fibrinolysis inhibitor, complement 
regulatory protein factor H and factor H related protein-1. Altogether, Scl proteins 
are structurally related and are involved in adhesion, host-cell entry, and immune 
evasion. The roles of the V and CL regions of Scl1 in ligand binding, as shown in 












Figure 2. Dichotomous binding of the Scl1 protein to human ligands. 
Cartoon depiction of the variable (V) region and collagen-like (CL) region of the 
Scl1 protein. The ligand/receptor and function (if known) are shown at left for 





Function of the CL Region of Scl1. Mammalian collagens promote 
essential eukaryotic cell functions, including cell attachment and migration via 
interactions with specific cellular receptors, the collagen-binding integrins 11, 
21, 101 and 111  (46, 55, 62). Since previous research identified the 
structural mimicry of the Scl-CL region with mammalian collagen, it was 
hypothesized that Scl proteins may also act as the collagen functional mimics 
and interact with human collagen integrin receptors. Humtsoe et al demonstrated 
that recombinant Scl1.41 (rScl1.41) protein, derived from M41-type GAS, 
designated P176, supported the attachment of human lung fibroblasts and 
promoted cell spreading. This, in turn, induced intracellular signaling resulting in 
the phosphorylation of several molecules of the integrin pathway, including FAK, 
CAS, paxillin, and JNK (46). Subsequent experiments determined that the Scl-CL 
region was responsible for binding to 21 and 111, but not 11 integrins. An 
additional study determined that the native Scl1.41 protein expressed on the 
GAS surface promoted GAS internalization by human pharyngeal epithelial cells, 
which was mediated by the Scl1 binding to 21  integrin. Internalization and 
intracellular survival resulted in enhanced re-emergence of GAS from the human 
cells, thus, providing a potential mechanism to avoid antibiotic killing (11). 
Subsequent work established that multiple human cell types expressing 21 and 
111 integrins internalize GAS through direct interactions between Scl1 and 
integrin receptors (12). These investigations were further supported by the work 
of Chen and coworkers, which showed a decrease in epithelial cell binding by the 
Scl1-negative mutants and an increased binding of the E. coli cells expressing 
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Scl1 on the surface (14). In total, this work demonstrates that Scl1 is both the 
structural and functional collagen mimic.  
Function of the V Region of Scl1. Extensive studies done to identify 
potential ligands for the Scl proteins have uncovered two distinct binding patterns 
associated with the V regions of different Scl1 variants (Figure 2). As discussed 
in the paragraphs below, our lab has previously identified that multiple rScl1 
variants derived from GAS strains of various M-types bound to apolipoprotein 
B100 (ApoB100), which is a sole protein component of LDL, while others bound 
the complement factor H (CFH) and complement factor H-related protein-1 
(CFHR1) (13, 39, 99). In this work, we established that those binding to LDL also 
interact with the extracellular matrix components, cellular fibronectin (discussed 
in the following Chapters), as well as, laminin. This dichotomous binding pattern 
is represented in Figure 2.  
In Han et al, the interaction of the Scl1-ApoB100 was characterized (39). 
In a series of ELISA-based studies, it was identified that rScl1 proteins derived 
from M1-, M12-, M28-, and M41-type GAS strains bound to purified 
LDL/ApoB100, the primary transport molecule in lipid metabolism. Surface 
plasmon resonance was used to quantify the specificity of Scl1-LDL binding. To 
determine the binding location of LDL on the Scl1 protein, chimeric recombinant 
proteins, generated by domain swapping, were used in binding studies. Results 
showed that the V region supported the interaction, which was further confirmed 
visually with electron microscopy (EM). Rotary shadowed samples containing 
mixtures of rScl1.41 and LDL vesicles revealed that LDL was interacting with 
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Scl1 via its globular, amino-terminal domain, indicating the V region. Lastly, Scl1-
mediated binding of LDL to GAS cells was assessed by comparing the 
absorption of plasma LDL and FITC-LDL to M28 wild-type and scl1-inactivated 
isogenic mutant cells. Both western blot analysis and fluorescent microscopy 
demonstrated that only the wild-type strain expressing the native Scl1 bound 
LDL, whereas binding by the mutant strain was absent. The function of the Scl1-
LDL interaction remains unclear. However, due to that LDL receptors are found 
on multiple cells and are important in host defense, it was proposed that the 
Scl1-LDL interaction may facilitate GAS innate immune evasion by altering early 
inflammatory responses initiated by macrophages during GAS infection (39).  
In Caswell et al, the interactions of the Scl1 proteins with CFH and CFHR-
1 were identified and characterized (13, 99). Affinity chromatography and 
subsequent mass spectrometry analysis revealed that Scl1.6 protein derived 
from the M6-type GAS strain bound to human plasma CFH and CFHR-1. CFH 
functions as a regulatory protein in the alternative complement pathway and 
prevents non-specific complement activation. Specifically, CFH acts as a cofactor 
to the serum protease, Factor I, in the cleavage of C3b and the decay of the C3-
convertase. This, in turn, helps to inhibit the production of opsonins and 
chemoattractants that would otherwise build up on self-cell surfaces and initiate 
phagocytic destruction. The sequestering of CFH on the bacterial surface mimics 
this mechanism and allows them to evade the innate immune response. CFH is 
composed of twenty (1-20) short consensus repeats (SCR). CFHR-1 contains 5 
SCRs and SCRs 3-5 are nearly identical in sequence with the C-terminal SCRs 
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18-20 of CFH. To determine the Scl1 domain supporting CFH/CFHR-1 binding, 
chimeric rScl proteins were generated through domain swapping of the V and CL 
regions. ELISA-based binding studies and western blot analysis showed that the 
Scl1-CFH/CFHR-1 interaction was mediated through the V region of Scl1.6. A 
modified in vitro assay was performed to demonstrate that the Scl1-bound CFH 
indeed maintained its biological activity as a co-factor for factor FI-mediated C3b 
cleavage. Finally, to assess whether native Scl1 on GAS surface supports CFH 
binding, a ligand affinity assay was performed using GAS cell wall material. It 
was shown that CFH bound a single protein band corresponding to the Scl1.6 
protein. Surprisingly, this assay did not show CFH binding by the M6 protein, 
which was originally reported to interact with both CFH and complement factor H-
like protein-1 (6, 53, 86). In total, this work confirmed CFH and CFHR-1 as 
ligands for the Scl1 protein of M6-type GAS and suggests that GAS may utilize 
the Scl1-CFH interaction to evade innate immune defenses (13, 45, 49, 85). 
Final Remarks. As GAS continues to be a major human pathogen and 
maintains its prevalence globally, the requirement for knowledge of pathogenesis 
mechanisms and contributing surface-associated and secreted virulence factors 
remains constant. In support of this, a major finding within the present body of 
work as defined in the following Chapters, is that the ubiquitous, surface-
associated Scl1 protein representing pathogenically different M-types is now 
among the list of GAS Fn-binding virulence factors with a unique specificity 
toward a spliced-variant of cFn. This finding represents a novel and purposeful 
mechanism by which GAS utilizes Scl1 to secure adherence in the wounded 
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tissue promoting colonization and biofilm formation, by specifically targeting the 
extracellular matrix during the process of wound healing. 
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The streptococcal collagen-like protein-1, Scl1, is widely expressed by the well-
recognized human pathogen group A Streptococcus (GAS). Screening of human 
ligands for binding to recombinant Scl1 identified cellular fibronectin and laminin 
as binding partners. Both ligands interacted with the globular domain of Scl1, 
which is also able to bind the low-density lipoprotein. Native Scl1 mediated GAS 
adherence to ligand-coated glass cover slips and promoted GAS internalization 
into HEp-2 cells. This work identifies new ligands of the Scl1 protein that are 
known to be important in GAS pathogenesis and suggests a novel ligand-
switching mechanism between blood and tissue environments, thereby 





Group A streptococci (GAS) typically colonize the human throat and skin causing 
superficial infections, such as pharyngitis and impetigo respectively. However, 
GAS infections may also lead to invasive diseases including necrotizing fasciitis 
and streptococcal toxic shock syndrome or may result in the postinfectious 
autoimmune sequelae acute rheumatic fever and acute glomerulonephritis (10). 
Host colonization is accomplished through interactions between GAS cell-surface 
adhesins and host cellular receptors or extracellular matrix components (ECM). 
Depending on the strain, GAS may express multiple surface proteins, including 
the streptococcal collagen-like proteins Scl1 (21, 29) and Scl2 (22, 28, 34).   
Structurally, Scl1 and Scl2 proteins contain a signature central collagen-
like (CL) region, which is composed of a repeating Gly-Xaa-Yaa sequence 
capable of adopting a stable triple helical structure similar to mammalian 
collagens (35). This structural mimicry by the CL region has been shown to 
support direct interactions with collagen-binding integrins (17) and mediate GAS 
adherence to and internalization by human cells (5). 
The amino-terminal part of the Scl proteins, termed the variable (V) region, 
forms a globular domain which is protruded away from the GAS-cell surface by 
the CL region (35). The V-region sequences vary significantly between Scl1 and 
Scl2. In addition, the V-region sequence of each Scl protein is conserved in 
strains of the same M-type but differs considerably among Scls from strains of 
different M-types. Despite the observed sequence variation, two main ligands 
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have been identified that bind different Scl1 variants via their V-regions. The 
Scl1.6 and Scl1.55 proteins of M6- and M55-type GAS respectively, bind human 
plasma glycoproteins factor H and the factor H-related protein 1 (4). On the 
contrary, several other Scl1 variants bind the low-density lipoprotein (LDL) 
including Scl1 proteins of the M1-, M2-, M12-, M28-, and M41-type GAS (14). 
The latter Scl1.41 protein also binds integrins α2β1 and α11β1 via direct interaction 
with the CL region (6). This suggests specialization in ligand binding among Scl1 
proteins and their importance as pathogenicity traits. 
The binding of the extracellular matrix (ECM) components by pathogens is 
known to be a common strategy used to establish host colonization. Several 
GAS cell-surface molecules have been reported to initiate this interaction 
including several M proteins, F1/SfbI, F2, SOF, SfbII, Lbp and Shr (7, 13, 16, 18, 
19, 24, 31). Thus, in this work, we hypothesized that Scl proteins possess 
binding capacities to ECM components that, in turn, would facilitate bacterial 
adhesion to human extracellular matrix and internalization by host cells. It is 
known that Scl1 is expressed by virtually all GAS strains (21, 29); therefore, this 
work further supports the role of Scl1 protein as an important accessory, 








Materials and methods 
GAS strains and growth conditions. The M41-type MGAS 6183 wild-type and 
the scl1 mutant strain were used. The isogenic scl1 mutant of MGAS 6183 was 
constructed by allelic replacement as described previously (5). To prepare GAS 
cells for experiments, cultures were grown overnight on brain–heart infusion agar 
(BD Biosciences, Sparks, MD) at 37°C in an atmosphere of 5% CO2-20% O2. 
Overnight cultures were used to inoculate Todd-Hewitt broth (BD Biosciences) 
supplemented with 0.2% yeast extract and the cultures were incubated at 37°C 
until they reached logarithmic phase of growth (OD600 ~0.5). The bacteria were 
collected by centrifugation, washed and then suspended in phosphate-buffered 
saline (PBS) at the desired cell concentration, which was verified by plating on 
tryptic soy agar containing 5% sheep’s blood (Remel, Lenexa, KS).  
 
Enzyme-linked immunosorbent assays (ELISA). Recombinant Scl (rScl) 
proteins used in ELISA were expressed in E. coli and purified by affinity 
chromatography using the Strep-tag II system (IBA-GmbH, Goettingen, 
Germany) as described previously (15, 35). Briefly, the DNA fragments of several 
scl1 and scl2 alleles, encoding the extracellular portions of the Scl1 and Scl2 
proteins, were amplified by polymerase chain reaction with Deep Vent Taq 
Polymerase (New England Biolabs, Beverly, MA) and cloned into the pASK-IBA2 
vector designed for periplasmic expression.   
Recombinant Scl proteins (0.5 µM) were immobilized onto Strep-Tactin-
coated microplate wells for 1.5 hours at room temperature. Following overnight 
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blocking with Tris-buffered saline (TBS) supplemented with 1% bovine serum 
albumin (BSA) at 4oC, 1 µg of each ligand that included plasma fibronectin (pFn), 
cellular fibronectin (cFn), laminin (Lm), bovine collagen types I and IV, decorin, 
heparin, and fibrinogen (all proteins were purchased from Sigma) was added to 
triplicate wells and the mixture was incubated at room temperature for 1 hour. 
rScl-bound ligands were detected with specific primary antibodies and 
appropriate secondary antibodies conjugated to horseradish peroxidase (HRP). 
The HRP reaction was developed with 2, 2'-azino-bis (3-ethylbenzthiazoline-6-
sulfonic acid) (ABTS) substrate and recorded at OD415 after 15 minutes of color 
development. 
In the ligand competition experiments, purified cFn and Lm were used in a 
molar ratio 1:1. First, the primary ligands e.g., cFn or Lm, were added to triplicate 
wells immobilized with P176 and incubated for 1 h at room temperature. 
Following washes with TBS, secondary ligands were added to the appropriate 
wells e.g., Lm was added to wells containing Scl1-cFn complex and vice versa; 
samples were incubated for 1 h at room temperature. Subsequently, the ELISA 
proceeded as described above. 
 
GAS whole-cell attachment assay to ECM proteins. To generate GFP-
expressing GAS cells, the wild-type strain, the scl1-inactivated mutant, and 
mutant complemented in-trans for Scl1.41-protein expression (plasmid pSL230) 
(5) were transformed with the plasmid pSB027 (8). Glass cover slips were placed 
in the wells of 24-well tissue culture plates and coated with 2.5 g of purified 
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ECM proteins or BSA overnight at 4oC, and subsequently blocked with 1% BSA 
in TBS for 1 h. Approximately 1x107 CFU of fluorescent GAS cells were added to 
each well for 1 h at room temperature and unbound cells were removed by 
washing with PBS. ECM-bound GAS cells were fixed with 3% para-formaldehyde 
in PBS for 30 min. The cover slips were removed from the wells, air-dried, placed 
on microscope slides, and viewed by fluorescent microscopy using a 450-490 nm 
excitation channel at 400x and 1000x magnification. For quantification, GAS cells 
were counted in 10 random fields under 1000x magnification.  
 
GAS internalization assays. An antibiotic protection assay was employed for 
GAS internalization as described previously (5) with some modifications. Briefly, 
human HEp-2 cells were grown in 24-well tissue culture plates until semi-
confluent. All co-culture experiments were performed in serum-free and ECM-
free Delbeco’s Modified Eagle Medium (DMEM). For ECM treatment, 10 ml of 
1x107 CFU/ml of each prepared GAS strain was pre-incubated with 15 µg of 
purified cFn or Lm for 1 hour at room temperature on an end-over-end rotator. 
Subsequently, ~1x106 CFU of ECM-treated or ECM-untreated wild type or scl1-
inactivated mutant GAS were co-cultured with the HEp-2 cells (MOI 1:100) for 2 
hours at 37oC.  Cell layers were washed with PBS, and culture medium 
containing 100 µg·ml-1 gentamicin and 5 µg·ml-1 penicillin G was added to each 
well to kill extracellular bacteria. After 2 hours, the medium was removed and the 
cells were washed with PBS. To determine the level of GAS internalization, the 
epithelial cells were lysed in distilled water and serial dilutions were plated onto 
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blood agar. The internalization level of ECM-untreated wild-type strain was 
considered 100%.  
 
Statistical analysis. Statistical significance was determined using a two-tailed 
paired Student’s t-test. The results were considered statistically significant with 
P< 0.05(*), P< 0.01(**), and P< 0.001(***).   
 
Results and discussion 
M41-serotype strains of GAS have emerged as a major cause of streptococcal 
impetigo during 1950s and 1960s (2). They were isolated from skin infections in 
several geographical locations, including Minnesota (32), Alabama (12), and 
Trinidad (11) with frequencies of 12-14% of all cases. The M41-type isolates 
were also reported in a recent GAS surveillance study of patients with invasive 
infections in the United States (25). Strain MGAS 6183 used here was cultured 
from a leg abscess during the epidemics of invasive GAS infections in Texas.  
We have previously reported that the recombinant Scl1.41 protein, 
designated P176, bound human collagen receptors via its collagen-like (CL) 
region and LDL via the variable (V) region (6, 14). Here, we evaluated the 
binding of an array of potential human ligands, including several ECM proteins, to 
the recombinant P176 by ELISA (Fig. 1a). We also used recombinant construct 
P163, derived from Scl2 protein of M28-type GAS, for which no ligands have 
been identified to date. None of the ligands tested here bound to the recombinant 
protein P163. No significant binding to P176 was detected for fibrinogen, decorin, 
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heparin, and collagens I and IV (data not shown). Remarkably, P176 bound 
cellular fibronectin (cFn) but not plasma fibronectin (pFn). The observation that 
Scl1 binds to cFn but not pFn is novel and very intriguing. Various forms of Fn 
are products of alternatively spliced mRNA transcript of a single gene containing 
about 50 exons (1). The pFn form is predominantly produced by hepatocytes and 
circulates in plasma as a covalently linked dimer. More heterogeneous cFn is 
produced by many cell types and forms large aggregated structures known as 
fibronectin fibrils. The cFn comprises a large group of isoforms produced from 
splicing events that may or may not include the type III repeats called extra 
domains, EDA and EDB, lacking in pFn (26). It is currently not known whether 
the presence of the extra domains or supra structural organization is responsible 
for the selective binding of cFn to Scl1 protein.  
In addition to cFn, P176 also bound laminin (Lm). The cFn and Lm binding 
to P176 was concentration-dependent indicating binding specificity (Fig. 1a, 
inset). The laminins comprise a family of A, B1 and B2 heterotrimeric 
glycoproteins that are constituents of basal lamina and are found in virtually all 
human tissues (1). Various isoforms of laminin exist that are associated with 
characteristic tissue distribution. Early studies by Switalski et al. described GAS 
binding to Lm, although the GAS product responsible for this binding was not 
identified (30). Terao et al. identified a GAS Lm-binding protein, designated Lbp 
(31), which was recently characterized as primarily a zinc-binding protein with 
capacity to bind Lm (20). GAS interactions with Lm were also attributed to 
another streptococcal protein Shr that primarily binds human plasma 
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hemoproteins (13). Thus, unrelated surface proteins of GAS possess binding 
capacities towards extracellular matrix components Fn and Lm. 
Since both cFn and Lm contain the collagen-binding domains (1), we 
could not exclude a possibility that the CL region of Scl1 was responsible for 
ECM binding. Therefore, we constructed a chimeric recombinant protein by 
domain swapping consisting of the V-region of P176 and the CL-region of the 
ECM-binding-negative protein P163. The resulting construct P181 bound cFn 
and Lm indicating that ECM-binding is mediated by the P176-V region (Fig. 1a). 
We next devised a competition assay to investigate whether cFn and Lm binding 
is localized to the same site within P176 V-region (Fig. 1b). First, immobilized 
P176 was incubated with one of the primary ECM ligands, cFn or Lm, and then 
incubated with an alternate secondary ECM ligand. Sets of triplicate wells were 
immunoreacted with antibodies specific for both ECM ligands to assess the 
presence of cFn and Lm attached to P176. Immunoreactivity of the same 
amounts of P176-cFn and P176-Lm were considered as 100% binding (Fig. 1b; 
bars 1-2). Pre-incubation of P176 with cFn did not prevent Lm binding (bar 4) nor 
Lm displaced the cFn from P176 (bar 3). Likewise, pre-incubation with Lm did not 
prevent cFn binding to P176 (bar 5) nor cFn was able to displace the Lm from 
P176 (bar 6). Our data suggest that under these experimental conditions, the cFn 
and Lm did not compete for binding to P176. 
Binding between rScl1.41 construct P176 and ECM proteins may not 
translate into binding between GAS-expressed Scl1.41 protein and ECM 
components. Therefore, a whole-cell binding assay (Fig. 2) was carried out using 
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the wild-type MGAS 6183 strain, the scl1-inactivated isogenic mutant, and the 
mutant complemented with plasmid pSL230 expressing in-trans the Scl1.41 
protein (5). All three strains were first transformed with the plasmid pSB027 to 
generate GFP-expressing cells (Fig. 2a, images at left). The stability of two 
plasmids pSL230 and pSB027 within the complemented mutant strain was 
confirmed by isolating total DNA from these cells (Fig. 2d). Fluorescent GAS 
strains were next tested for binding to ECM-coated glass cover slips (Fig. 2a, 
images at middle and right columns). More fluorescent wild-type cells were seen 
attached to the cover slips coated with cFn and Lm, as compared with scl1 
mutant GAS. Furthermore, complementation of the scl1 mutant with pSL230 
considerably increased cell binding to both ECMs. Quantitative analysis by 
counting the numbers of GAS cells in random fields fully supported visual 
observations (Fig. 2b). The scl1-inactivated mutant bound 30% and 45% less to 
cFn and Lm, respectively, compared to the wild-type strain. Importantly, the 
complementation of mutant for Scl1.41 expression restored the wild-type levels 
of binding to both cFn and Lm, indicating that this phenotype was due to the lack 
of Scl1 expression. Residual cFn binding by the Scl1 mutant could be attributed 
to the presence of the prtf2 gene in this strain (5) encoding an additional Fn-
binding protein, F2 (18). Similarly, the observed binding of the Scl1-deficient 
mutant to Lm could be attributed to Lbp and Shr expression; however, the M41-
type GAS was not included in the studies that characterized these ECM-binding 
proteins (13, 31). Since lbp and shr genes are conserved among GAS strains of 
various M types, we used PCR to demonstrate the presence of both genes in 
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M41-type strain MGAS 6183 (Fig. 2c). Altogether, our results demonstrate that 
Scl1.41 protein is an important surface adhesin that selectively binds to human 
cellular fibronectin and laminin and significantly contributes to ECM-GAS 
interactions. 
GAS interactions with ECM components have been exhaustively reported 
in the literature and much effort has been directed toward understanding its 
function in GAS adherence and internalization pertaining to human disease (9). 
The bulk of that work focuses on Fn, although the effect of exogenous cFn on 
GAS internalization was not specifically investigated. Far less is known about the 
contribution of Lm to GAS adherence and internalization. Recently, the Lm-
binding protein Lbp of the M1-type strain was shown to facilitate the adherence to 
and internalization by HEp-2 cells; however, the observed decrease in 
internalization of the lbp mutant was not statistically significant compared with the 
wild-type strain (31). In addition, a mutant strain of the M49-type GAS deficient in 
surface protein Shr, which binds both soluble Fn and Lm, showed decreased 
adherence to HEp-2 cells compared with the parental strain (13).  
In our current studies, the HEp-2 cells were co-cultured with the wild type 
or the isogenic scl1-inactivated mutant GAS that were either treated or untreated 
with cFn or Lm. Following internalization, the numbers of surviving intracellular 
bacteria were determined. The Scl1-deficient GAS cells were internalized 
significantly less than the wild type strain in ECM-free medium (Fig. 3). Following 
pre-incubation with cFn and Lm, the wild type strain exhibited about a 4- and 6.5-
fold increase in internalization, respectively, compared to ECM-untreated cells. 
34 
 
The scl1-inactivated strain pre-incubated with cFn and Lm also showed about 
2.2- and 2.8-fold increase in internalization compared to the ECM-untreated 
mutant cells; however, the overall levels of mutant internalization were lower 
compared to wild-type strain under each corresponding experimental conditions, 
emphasizing the contribution of Scl1 to cell invasion by GAS. It should be noted 
that the in vivo relevance of GAS internalization by human cells mediated by 
ECM binding has been debated in recent years. In spite of this, recent 
investigations using NMR spectroscopy, circular dichroism analyses, and 
experiments with monoclonal antibodies identified structural changes exerted by 
fibronectin upon binding to bacterial proteins that result in an enhanced Fn 
recognition by integrins (3, 23). It is tempting to speculate that Scl1 binding to 
cFn and Lm may exert similar biological effects. 
It was shown previously by our group that Scl1 from M41-type GAS binds 
the human collagen integrin receptors, which mediates GAS internalization by 
host cells (5, 6). Integrins bind directly the GLPGER sequence within the Scl1-CL 
region. Here, we show the V region of the same Scl1.41 protein binds to cFn and 
Lm, which also increases GAS internalization by HEp-2 cells. We think it is 
unlikely that cFn and Lm binding to the globular V domain affects Scl1-CL region 
binding to 21 and 111; however, we cannot fully exclude such a possibility. 
The HEp-2 cells express the 2,3,5, and 1 integrin subunits (5), thus are 
capable of producing the 21,31, and 51 heterodimers with ability to bind 
collagen, laminin, and fibronectin, respectively (33). The 111 integrin expression 
is restricted to fibroblasts (27) and, thus, may not be present on the surface of 
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HEp-2 cells. Therefore, Scl1 may be contributing to internalization of M41-type 
GAS by HEp-2 cells by two mechanisms: direct binding to the 21 integrin, and 
ECM-bridging mechanism via integrins 31 and 51.  
In a final series of experiments we tested several available rScl1 and rScl2 
constructs for binding to the same panel of human ligands employing an ELISA-
based assay. Similar to P176, no significant binding by any rScl protein was 
detected for fibrinogen, decorin, heparin, collagens type I and IV (data not 
shown). In general, the recombinant rScl1 constructs, derived from Scl1 proteins, 
bound cFn and Lm (Fig. 4a); while the Scl2-protein-based constructs P163, 
P177, and P178 were ECM-binding negative. Furthermore, none of the rScl1 
proteins tested bound pFn, which is in agreement with our previous reports 
showing that those rScl1 proteins did not bind pFn from human plasma by affinity 
chromatography (4, 15). All LDL-binding constructs derived from Scl1 proteins of 
the M1-, M28-, M41-, M12-, M2-, and M52-type GAS (15) showed ECM binding, 
although to varying degrees. However, the CFH/CFHR-1-binding rScl1s 
originating from the M6- and M55-type GAS (4) did not show any significant 
binding to ECM ligands. In order to determine the region of Scl1 responsible for 
binding to ECM proteins, an ELISA was performed using chimeric rScl constructs 
generated by domain-swapping (Fig. 4b). We employed two types of chimeric 
molecules: (i) derived from the ECM-binding positive (+) construct P144 (Scl1.1 
of M1-type GAS) and the ECM-binding negative (-) construct P177 (Scl2 of M4-
type GAS); and (ii) constructs derived from the ECM-binding positive P144 and 
the ECM-binding negative P179 (Scl1 of M6-type GAS). The rScl1 (+)-rScl2 (-) 
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chimeric construct P183 (P144V/P177CL) but not P184 (P177V/P144CL) bound 
cFn and Lm. Likewise, the rScl1 (+)-rScl1 (-) chimeric construct P213 
(P144V/P179CL) but not P212 (P179V/P144CL) bound cFn and Lm. These data 
strongly indicate that, indeed, the Scl1-V region is responsible for mediating 
interactions with ECM proteins.  
The present and previous results underscore the functional diversity of the 
Scl1-V region. Of particular interest to us is the emergence of two main binding 
patterns among Scl1 variants. The more common pattern includes binding of 
plasma LDL and extracellular matrix components cFn and Lm, which may 
represent an intriguing adaptation of Scl1 to either the blood or tissue 
environment. Our previous molecular evolutionary genetic analysis identified an 
elevated constraint of the Scl1-V region sequence suggesting that this region 
responds to selective pressure (21). Inasmuch as the amino acid sequence in the 
V region differs between Scl1 proteins of different M-types, the prediction of two 
α-helices (14, 29) and the globular structure of the Scl1-V domain (15, 35) seem 
to be conserved among all Scl1 proteins. The present work provides a platform 
for future investigations that will determine the Scl1-ECM binding affinities and 
identify the specific amino acid sequences or structural motifs of Scl1 variants 
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Figure 1. Characterization of ECM binding to rScl1.41 protein. (a) 
Recombinant Scl1.41 protein (P176) binds cellular fibronectin and laminin. 
Recombinant proteins P176, P163, and P181 containing portions of P176 and 
P163 were tested by ELISA for binding to purified plasma fibronectin (pFn), 
cellular fibronectin (cFn), or laminin (Lm). Graph bars represent the mean OD415 
±SD of triplicate wells. (Inset): Concentration-dependent binding of cFn and Lm 
to P176. (b) Competition between cFN and Lm for binding to P176. Immobilized 
recombinant protein P176 was pre-incubated with either cFN prior to incubation 
with Lm and vice versa. Scl1-ECM complexes were immunoreacted with anti-cFn 
and anti-Lm Abs. Immunoreactivity of the same amounts of P176-cFn and P176-
Lm were considered as 100% binding. Data is from a single experiment that is 







Figure 2. Scl1.41-mediated binding of GAS cells to ECM proteins. (a) 
Attachment of GAS cells expressing GFP marker on pSB027 to ECM-coated 
cover slips. Bound wild-type strain (6183::pSB027), the scl1-inactivated mutant 
(6183 scl1::pSB027), and the scl1 mutant complemented with plasmid pSL230 to 
express Scl1.41 (6183 scl1::pSL230::pSB027) were examined under the 
fluorescent microscope at 400x and 1000x magnification. Scale bars represent 
10µm. (b) Quantification of ECM-bound GAS. GAS cells attached to ECM-coated 
cover slips were counted at 1000x magnification. Binding of the wild-type GAS 
was considered 100%. Statistical significance was determined at a level of P< 
0.001 (***). (c) Presence of the lbp and shr genes in M1- and M41-type GAS. 
Genomic DNA from MGAS 5005 (M1) and MGAS 6183 (M41) were used as 
templates for PCR using primer sets: lbpFor (ACCGTCTGTAAATGATGTGG) 
and lbpRev (CATATGATGCTTACCAAGTTG), and shrFor 
(GTGCGTTTGTGCAATATCTG) and shrRev (AGCGTATAGGTTCCTTCTGTG). 
PCR products were detected by ethidium bromide agarose gel electrophoresis. 
M; 1-kb DNA marker. (d) Stability of pSB027 and pSL230 in MGAS 6183. The 
presence of Scl1.41-expressing plasmid pSL230 and GFP-expressing plasmid 
pSB027 in the complemented scl1 mutant strain was tested. GAS genomic DNA 
was isolated and compared with pSL230 and pSB027 plasmid markers in 






















Figure 3. Scl1-ECM interactions mediate GAS internalization by human 
epithelial cells. HEp-2 cells were cocultured for 2 h in ECM-free media with the 
wild-type (WT) and the scl1-inactivated (scl1) GAS cells that were either 
retreated or untreated with cFn or Lm. Following antibiotic treatment, the 
numbers of intracellular bacteria were determined by plating the eukaryotic-cell 
lysates on blood agar. The results obtained with ECM-untreated wild-type GAS 
were considered 100%. All means (graphic bars) and standard deviations (error 
bars) are combined values from three independent experiments. Statistical 

























Figure 4. Characterization of ECM binding to rScl1 proteins. (a) Binding of 
pFn, cFn, and Lm to rScl proteins by ELISA. The designation of rScl constructs, 
as well as the GAS M-type from which each construct was derived (M-type), are 
indicated. The distinction between Scl1-derived (rScl1) and Scl2-derived (rScl2) 
proteins is shown. rScl- or BSA-bound ECM proteins were detected with specific 
antibodies. Graph bars represent the mean OD415 ±SD of triplicate wells from a 
single experiment that is representative of three independent experiments. The 
solid, dotted, and spaced lines represent binding of pFn, cFn, and Lm, 
respectively to the BSA-coated wells with average values plus 3 SD as negative 
controls.  (b) Identification of the Scl1 domain responsible for ECM binding. 
Chimeric rScl proteins, which were constructed by domain swapping between 
ECM-binding-positive and ECM-binding-negative rScls identified in panel (a), 
were tested for binding to cFn and Lm by ELISA. Domain composition of each 
chimeric molecule is shown below the graph. Graph bars represent the mean 
OD415 ±SD of triplicate wells from a single experiment that is representative of 
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Group A Streptococcus (GAS) is a human-specific pathogen responsible for a 
number of diseases characterized by a wide range of clinical manifestations. 
During host colonization GAS-cell aggregates or microcolonies are observed in 
tissues. GAS biofilm, which is an in vitro equivalent of tissue microcolony, has 
only recently been studied and little is known about the specific surface 
determinants that aid biofilm formation. In this study, we demonstrate that 
surface-associated streptococcal collagen-like protein-1 (Scl1) plays an important 
role in GAS biofilm formation. Biofilm formation by M1-, M3-, M28-, and M41-type 
GAS strains, representing an intraspecies breadth, were analyzed 
spectrophotometrically following crystal violet staining, and characterized using 
confocal and field emission scanning electron microscopy. The M41-type strain 
formed the most robust biofilm under static conditions, followed by M28- and M1-
type strains, while the M3-type strains analyzed here did not form biofilm under 
the same experimental conditions. Differences in architecture and cell-surface 
morphology were observed in biofilms formed by the M1- and M41-wild-type 
strains, accompanied by varying amounts of deposited extracellular matrix and 
differences in cell-to-cell junctions within each biofilm. Importantly, all Scl1-
negative mutants examined showed significantly decreased ability to form biofilm 
in vitro. Furthermore, the Scl1 protein expressed on the surface of a 
heterologous host, Lactococcus lactis, was sufficient to induce biofilm formation 
by this organism. Overall, this work (i) identifies variations in biofilm formation 
capacity among pathogenically different GAS strains, (ii) identifies GAS surface 
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properties that may aid in biofilm stability and, (iii) establishes that the Scl1 
surface protein is an important determinant of GAS biofilm, which is sufficient to 
enable biofilm formation in the heterologous host Lactococcus. In summary, the 






Microbial biofilm formation is an important virulence mechanism, which allows 
immune evasion and survival against antibiotic treatments (19, 64). Many 
bacterial nosocomial infections are associated with biofilms formed on 
contaminated medical devices. Dispersal of biofilm has also been proposed to 
augment infection spread (11, 20, 31, 36, 40, 42). For group A Streptococcus 
(GAS), biofilm research is an emerging field and little is known about the specific 
surface determinants that aid in biofilm formation. GAS is characteristically 
associated with significant human morbidity and it is responsible for the clinically 
common superficial throat and skin infections, such as pharyngitis and impetigo, 
as well as invasive soft tissue and blood infections like necrotizing fasciitis and 
toxic shock syndrome (24). Although GAS biofilm has not been associated with 
implanted medical devices, tissue microcolonies of GAS encased in an 
extracellular matrix were demonstrated in human clinical specimens (1). Studies 
reported to date support the involvement of GAS surface components in biofilm 
formation, including the M and M-like proteins, hyaluronic acid capsule, pili and 
lipoteichoic acid (18, 22, 52). As shown by Cho and Caparon (18), multiple genes 
are upregulated during biofilm formation and development, including the 
streptococcal collagen-like protein-1 (Scl1).   
The scl1 gene encoding the Scl1 protein has been found in every GAS 
strain investigated and its transcription is positively regulated by Mga (2, 3, 46, 
47, 60), indicating that Scl1 is co-expressed with a number of proven virulence 
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factors. Structurally, the extracellular portion of Scl1 protein extends from the 
GAS surface as a homotrimeric molecule composed of distinct domains that 
include the most outward N-terminal variable (V) region and the adjacent 
collagen-like (CL) region composed of repeating GlyXaaYaa (GXY) sequence. 
The linker (L) region is close to the cell surface and contains a series of 
conserved direct repeats. The Scl1 protein can bind selected human extracellular 
matrix components (17) and cellular integrin receptors (15, 16, 37), as well as 
plasma components (14, 27, 34, 55, 61).  
In this study, we investigated the importance of Scl1 in GAS biofilm using 
defined isogenic wild-type and scl1-inactivated mutant strains of GAS. We report 
that (i) the pathogenically diverse M41-, M28-, M3- and M1-type GAS wild-type 
strains have varying capacities to produce biofilm on an abiotic surface; (ii) Scl1 
plays an important role during the main stages of biofilm formation with Scl1-
negative mutants having an abrogated capacity for adhesion, microcolony 
formation and biofilm maturation; and (iii) variations in surface morphology as 
well as in extracellular matrix associated with bacterial cells suggest two distinct 
but plausible mechanisms that potentially stabilize bacterial microcolonies. We 
additionally show that expression of Scl1 in Lactococcus lactis is sufficient to 
support a biofilm phenotype. Overall, this work reveals a significant role for the 
Scl1 protein as a cell-surface component during GAS biofilm formation among 
pathogenically varying strains. 
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Materials and Methods 
 
GAS strains and growth conditions. The wild-type GAS strains M41- 
MGAS6183, M1- MGAS5005, and M28-type MGAS6143, as well as their scl1-
inactivated isogenic mutants and complemented M41Δscl1 mutant have been 
previously described (16, 34, 45). In addition, a set of the wild-type M3-type GAS 
strains MGAS158, MGAS274, MGAS315, MGAS335, MGAS1313, and 
MGAS2079 was also used. GAS cultures were routinely grown on brain–heart 
infusion agar (BD Biosciences) and in Todd–Hewitt broth (BD Biosciences) 
supplemented with 0.2% yeast extract (THY medium) at 37oC in an atmosphere 
of 5% CO2–20% O2. Logarithmic phase cultures harvested at the optical density 
(600 nm) of about 0.5 (OD600 ~0.5) were used to prepare GAS inocula for biofilm 
analysis. Colony counts were verified by plating on tryptic soy agar with 5% 
sheep’s blood (Remel). Lactococcus lactis subsp. cremoris strain MG1363 
(provided by Dr. Anton Steen) were grown using M17 broth or agar media 
(Oxoid) supplemented with 0.5 M sucrose and 0.5% glucose (SGM17 media) at 
30oC in an atmosphere of 5% CO2–20% O2. 
 
Heterologous Scl1 expression in Lactococcus lactis 
Lactococcus transformation. To obtain electrocompetent cells, 500 ml of 
SGM17 broth supplemented with 2% glycine was inoculated with an overnight 
culture and grown until OD600 ~0.4 was reached. Cells were harvested and 
washed twice with ice-cold solution A (0.5 M sucrose, 10% glycerol); cells were 
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then re-suspended in solution A (1/1000 of original culture volume) and stored at 
-80oC (35). For transformation, cells were thawed on ice and mixed with 1 l of 
DNA of the Scl1.41-expressing plasmid pSL230 or pJRS525-vector(16); and 
transferred to a cold 1-mm electrode-gap cuvette. Cells were pulsed with 2.0 kV 
at 25 F and 400 ohms. Immediately following, suspensions were mixed with 1 
ml outgrowth medium (SGM17 broth supplemented with 20 mM MgCl2 and 2 mM 
CaCl2) and incubated for 2.5 h before plating on SGM17 agar supplemented with 
spectinomycin (59). 
 
Molecular characterization of transformants. The pSL230 was detected in 
Lactococcus lactis MG1363 transformants by PCR amplification directly from 
bacterial colonies with scl1.41-gene specific primers 232up (5’-
CTCCACAAAGAGTGATCAGTC) and 232rev (5’-
TTAGTTGTTTTCTTTGCGTTT); pSL230 plasmid DNA was used as a positive 
control. PCR samples were analyzed on 1% agarose gel in Tris-acetate-EDTA 
buffer and stained with ethidium bromide. Inocula from colonies of L. lactis 
MG1363, as well as colonies harboring either pJRS525 vector or pSL230 
construct were used in subsequent experiments.  
 
Western blot analysis. Cell-wall extracts were prepared as previously described 
(16). Briefly, cells grown to OD600 ~0.4 were harvested, washed with TES (10 mM 
Tris, 1mM EDTA, 25% Sucrose), re-suspended in TES-LMR (TES containing 
1mg/ml hen egg lysozyme, 0.1 mg/ml mutanolysin, 0.1 mg/ml RNAseA and 1 mM 
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PMSF) and incubated at 37oC for 1 h. After centrifugation at 2500g for 10 min, 
the supernatants were precipitated with ice-cold TCA (16% final) at -20oC 
overnight. Precipitates were rinsed thoroughly with ice-cold acetone and 
dissolved in 1x sample buffer at 250 l per unit OD600. Samples were subjected 
to 10% SDS-PAGE, transferred to nitrocellulose, and probed with anti-P176 
antiserum followed by goat anti-rabbit-HRP and detected employing 
chemiluminescent substrate (Pierce). 
 
Flow cytometry. Bacterial cells were grown to mid-log phase (OD600 ~0.4), 
washed once with filtered DPBS containing 1% FBS and re-suspended in the 
same buffer. Five million cells were incubated with 1:400 dilution of primary 
reagents, either rabbit pre-bleed (control) or rabbit anti-P176 antiserum for 30 
min on ice, washed with DPBS-FBS and then incubated with 1:200 dilution of 
second reagent donkey anti-rabbit-APC (Jackson ImmunoResearch) for 30 min 
on ice. After a final wash and re-suspension in DPBS-FBS, flow cytometric data 
were acquired with FACSCaliber (BD Biosciences) and analyzed employing FCS 
Express (De Novo Software). 
 
Analysis of biofilm formation 
Crystal violet staining assay:  Biofilm formation was tested using tissue culture 
treated polystyrene 24-well plates. 1.5 ml of logarithmic-phase GAS or 
Lactococcus cultures were seeded without dilution into wells and incubated at 
37oC for GAS and 30oC for Lactococcus in an atmosphere of 5% CO2–20% O2 
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according to indicated time points upon which medium was aspirated. Wells were 
washed with PBS and 500 µl of 1% crystal violet was added to each well, and 
incubated at room temperature for 30 min. Dye was then aspirated, wells were 
washed with PBS, and stain was solubilized with 500 µl of 100% ethanol. 
Spectrophotometric readings at OD600 were recorded for each sample per time 
point. Samples were analyzed in triplicate in at least three experiments. 
 
Confocal Laser Scanning Microscopy (CLSM). To visualize GAS and L. lactis 
strains by CLSM, bacterial cells were transformed with a GFP-encoding plasmid, 
pSB027 (23). 15-mm glass cover slips were placed into 24-well tissue culture 
plate wells. Logarithmic-phase bacterial cultures were inoculated without dilution 
and grown for 24 h. Cover slips were rinsed with PBS and fixed with 3% 
paraformaldehyde at room temperature for 30 min. Biofilms present on cover 
slips were washed with PBS and mounted onto slides using Prolong Gold 
mounting media (Invitrogen). Confocal images were acquired using a 63x/1.40 
Plan-Apochromat objective and a Zeiss LSM 510 laser scanning confocal on an 
AxioImager Z1 microscope. An orthogonal view of the Z-stacks was used to 
display and measure biofilm thickness using Zeiss LSM software. Ten 
representative images within a single experiment were used to calculate the 
average vertical thickness measured in micrometers.  
To visualize extracellular matrix associated with GAS cells, 24 h biofilm 
samples were reacted with 100 g of tetramethyl rhodamine isothiocyanate- 
(TRITC)-conjugated concanavalin A (TRITC-ConA) (Invitrogen) for 30 min at 
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room temperature in the dark prior to mounting with Prolong Gold medium. An 
average of ten microscopic views within each sample was reviewed using the 
63x/1.40 objective, as described above. 
 
Field emission scanning electron microscopy (FESEM).  GAS biofilm 
samples were grown for 24 h on glass cover slips, washed with PBS, and fixed 
with 3% paraformaldehyde for 2 h and post-fixed in osmium tetroxide. Samples 
were next dehydrated in an ethanol gradient, dried using hexamethyldisalizane, 
mounted onto aluminum stubs and sputter-coated with gold/palladium. The 
samples were then imaged on a Hitachi S-4800 field emission scanning electron 
microscope. 
 
Quantitation of hydrophobicity. A modified hexadecane method (22, 32, 56) 
was used to determine the cell hydrophobicity. Briefly, 5 ml of the logarithmic-
phase GAS or Lactococcus cultures (OD600 ~0.5) were pelleted, washed and re-
suspended in 5 ml of PBS. One ml of hexadecane was added, vortexed for 1 min 
and incubated for 10 min at 30oC. Mixtures were then vortexed for an additional 1 
min and allowed to stand for 2 min for phase separation at room temperature. 
The absorbance of the lower aqueous phase was read at OD600 and compared 
against the PBS control. Actual hydrophobicity value was calculated using the 
following equation: Actual Value = [1 – (A/Ao)] x 100, where A is OD600 value after 




Statistical analysis. Statistical significance was determined using a two-tailed 
paired Student’s t-test. The results were considered statistically significant with P 





Wild-type GAS strains have heterogeneous capacity for biofilm formation 
on abiotic surfaces. Biofilm formation was compared between M41-, M28-, M3- 
and M1-type GAS strains representing distinct epidemiological traits (Figure 1). 
To assess biofilm formation after 24 h, we used spectrophotometric 
measurements recorded following crystal violet staining (Figure 1A). Both the 
M41- and M28-type strains produced more biomass as compared with M1 strain. 
Furthermore, the M3-type strain produced the lowest absorbance values in a 
crystal violet assay, indicative of lower cell biomass, as compared with the other 
wild-type strains. These experiments confirm previous observations (19, 43) that 
GAS strains have varying capacity to form biofilm in vitro.  
The failure of M3-type strain MGAS315 to produce substantial cellular 
biomass in the above assay was intriguing because sequence analysis of the 
Scl1.1 allele found in MGAS315 revealed the presence of a TAA stop codon in 
the 11th GXY repeat of the Scl1.3-CL region containing a total of 25 GXY triplets 
(48). This premature stop codon results in a truncated Scl1.3 variant composed 
of 102 amino acids (~11.4 kDa), which does not contain the cell wall-membrane 
(WM) associated region, thus, preventing it from anchoring to the bacterial cell 
surface (Figure 1B). This prompted us to investigate the biofilm formation by five 
additional M3-type strains, all harboring the same scl1.3 allele. Five additional 
M3-type strains, MGAS335, MGAS1313, MGAS2079, MGAS274 and MGAS158, 
all harboring the same scl1.3 allele (48) also produced poor biofilm under static 
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conditions, as measured by crystal violet staining. Confocal laser scanning 
microscopy (CLSM) of three representative strains (MGAS315, MGAS2079, and 
MGAS158) corroborated results obtained from the crystal violet assay, indicating 
that these M3-type strains lack the ability to form appreciable biofilm structure. 
Our data suggest that the lack of capacity for biofilm-formation among M3-type 
GAS strains examined here might be correlated, at least in part, with lack of 
surface-attached Scl1.3 protein. 
 
Microscopic evaluation reveals differences in biofilm surface morphology. 
We next conducted microscopic analysis of the biofilms formed by the wild-type 
(WT) M41-, M28-, and M1-type GAS strains. First, we examined the overall 
structural characteristics of biofilms formed after 24 h using CLSM (Figure 4 D-
F); Additional file 1: Figure S1 A-F). The average biofilm thickness (see Methods 
section) differed among all three strains with M1 producing considerably thinner 
biofilm (mean value of 9 m) compared to M28 (12 m) and M41 (15 m), a 
result consistent with lower spectrophotometric absorbance values (Figure 1A). 
In addition to measured differences in biofilm thickness, closer examination of the 
X-Y orthogonal Z-stack views, representing biofilm cross-sections, revealed 
architectural differences among the M41, M28, and M1 biofilms. The M1 biofilm, 
although the thinnest, seems to consist of densely-packed cells that form 
continuous layers, while the M28 and especially M41 biofilms seem to be less 
dense but exhibit more elevated supracellular assembly. We therefore used field 
emission scanning electron microscopy (FESEM) to define more accurately 
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these supracellular differences observed by CLSM between the biofilms 
produced by the WT M1 and M41 GAS (Figure 2). FESEM exposed notable 
architectural differences between biofilms formed by these two strains. The M41 
(Figure 2, panel A) biofilm was characterized by more diverse surface 
architecture with the evidence of depressions or crypts, whereas the M1 biofilm 
(panel B) seems to lack such pronounced surface characteristics. At higher 
magnification, the M41 cells have a studded cell surface morphology with 
protrusions linking both sister cells and cells in adjacent chains (panel c). In 
contrast, the M1 cells had a relatively smoother appearance likely due to the rich 
bacterial-associated extracellular matrix (BAEM) surrounding these cells and 
covering their surface (panel d). BAEM material, which was clearly seen at higher 
resolution between the M1-type cells, was not as evident between cells of the 
M41-type GAS.  
 
GAS biofilms differ in production of bacterial-associated extracellular 
matrix. The production of BAEM has been shown to be an integral component in 
the structural integrity of a biofilm, imparting protection from dehydration, host 
immune attack, and antibiotic sensitivity (26, 39). GAS cells encased in a 
glycocalyx were first identified by Akiyama et al. in skin biopsies obtained from 
impetigo patients. We therefore compared the production of BAEM within biofilms 
employing GFP-expressing GAS strains of the M1 and M41 type (Figure 3). Cells 
were grown to form biofilms on glass cover slips for 24 h and stained with TRITC-
concanavalin A (ConA), a fluorescently-labeled lectin that binds to the 
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extracellular polysaccharides in biofilms (51). Fluorescent microscopy was 
performed to compare matrix production (red staining) by GAS strains (green). 
Visual screening of both biofilms indicated that the M41-type strain formed a 
more dispersed extracellular matrix as compared to the M1 strain, which had a 
dense, more closely associated matrix. In addition, averages of at least 10 fields 
of ConA stained matrix by CLSM support our FESEM observations that more 
BAEM is deposited within the biofilm by the M1 GAS cells as compared to M41 
GAS. This is in agreement with the report from Akiyama et al that showed a 
substantial FITC-ConA stained matrix associated with T1-type GAS 
microcolonies in vivo and in vitro (1).  
 
Scl1 protein significantly contributes to biofilm formation by GAS. 
Variations in GAS pathogenicity and capacity to form biofilm are driven by 
specific proteins and components present on the cell surface or are secreted by 
the organism. It has been shown that deletion of the M and M-like surface 
proteins or capsule, as well as increased expression of the secreted SpeB 
protease decreases biofilm formation dramatically for some strains of GAS (13, 
22, 25). Therefore, we investigated the role of Scl1 in biofilm formation by 
comparing biofilms formed by GAS WT and scl1-inactivated (Δscl1) mutant 
strains (Figure 4; Additional file 1: Figure S1 A-F). Bacterial biomass was 
evaluated spectrophotometrically following crystal violet staining at 1, 6, 12, and 
24 h time points, representing different stages of biofilm formation, and 
absorbance values rendered for the WT and Δscl1 isogenic mutant strains were 
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compared. The M41Δscl1 mutant showed a 29-35% decrease in biofilm 
formation (the OD600 value obtained for the WT strain at each time point was 
considered 100%), which was sustained throughout all time points. This 
reduction was statistically significant at initial adherence (1 h), as well as during 
biofilm development (6-12 h) and at maturation (24 h) (Figure 4A; P ≤ 0.05 at 1 
and 12 h, P ≤ 0.001 at 6 and 24 h). Complementation of Scl1.41 expression in 
the M41Δscl1 mutant (M41 C) restored its ability to form biofilm to WT levels. 
Similarly, the M28Δscl1 mutant had a significantly decreased capacity for biofilm 
formation in the range of 29-44% as compared to WT strain (Figure 4B; P ≤ 0.05 
at 1 and 6 h, P ≤ 0.001 at 3, 12 and 24 h). Likewise, there was a statistically 
significant decrease in M1Δscl1 biofilm biomass by ~42-75% compared to the 
WT strain (Figure 4C; P ≤ 0.001 at 1-24 h). CLSM analysis of corresponding 24-h 
biofilms of these strains confirmed our crystal violet staining results at 24 h. The 
Δscl1 mutants had substantially decreased average biofilm thickness by more 
than 50% (mean values) as compared to the parental WT organisms (Figure 4D-
F). While these low average biofilm thickness values measured for the M1Δscl41 
(6 M) and M28Δscl1 (5 M) correspond to residual biofilms made by those 
mutants (Figure S1 A-D), by comparison, the M1Δscl1 (4 M) was shown not to 
produce a continuous biofilm layer under these conditions (Figure S1 E-F). Our 
data support the hypothesis that the Scl1 protein plays an important functional 
role during GAS biofilm formation and that Scl1 contribution varies among GAS 




Scl1 expression affects surface hydrophobicity. The surface hydrophobicity 
of GAS has been shown to influence the adherence to abiotic surfaces. The 
presence of pili (52) , M and M-like proteins, and lipoteichoic acid contributes to 
cell surface hydrophobic properties (22, 66), which in turn may influence biofilm 
formation by GAS. Here, we have investigated the contribution of Scl1 to surface 
hydrophobicity of M41-, M28-, and M1-type GAS strains using a modified 
hexadecane binding assay (22, 33, 56). As shown in Table 1, the M28-type GAS 
strain MGAS6143 gave the highest actual hydrophobicity value of 94.3 ± 0.73, 
followed by the M41-type strain MGAS6183 (92.6 ± 0.86). In contrast, the overall 
surface hydrophobicity of the M1-type GAS strain MGAS5005 (80.3 ± 0.89) was 
significantly lower compared to both M28 and M41 strains (P ≤ 0.001 for each 
comparison). Inactivation of scl1.41 in M41-type GAS resulted in a modest, 
although statistically significant, reduction in the hydrophobicity index (100% for 
WT vs. 92% for mutant, P ≤ 0.001). In-trans complementation of the Scl1.41 
expression in M41Δscl1-C restored the hydrophobic phenotype of the cells to WT 
level (hydrophobicity index ~105%). In comparison, the contribution of the Scl1.1 
and Scl1.28 proteins to surface hydrophobicity is more substantial, as evidenced 
by a ~21% and ~22% reduction of the hydrophobicity indices of the mutants as 
compared to the corresponding WT strains, respectively (P ≤ 0.001 for both). 
Thus, the Scl1-mediated GAS-cell surface hydrophobicity reported here may 
contribute to the ability of this organism to form biofilm, as suggested for other 




Scl1 is sufficient to support biofilm formation in Lactococcus lactis. To 
assess whether Scl1 expression is sufficient to confer the ability for biofilm 
formation, we chose to express this protein in a heterologous L. lactis system 
(44, 57). The wild-type L. lactis strain MG1363 was transformed with plasmid 
pSL230 encoding the Scl1.41 protein (16) or with the shuttle vector pJRS525 
alone. As shown in Figure 5A, PCR amplification of the scl1.41 gene employing 
specific primers yielded no product from the WT L. lactis MG1363 (lane 1) and 
the MG1363::pJRS525 transformant (lane 2). A product of the expected size of 
1.4 kb was amplified from the pSL230 plasmid DNA control (lane 4,) as well as 
was amplified from the MG1363::pSL230 transformant (lane 3). Surface 
expression of Scl1.41 was confirmed by immunoblot analysis of cell-wall extracts 
prepared from L. lactis WT, and the MG1363::pJRS525 and MG1363::pSL230 
transformants, as well as MGAS6163 (WT M41 GAS). As shown in Figure 5B, 
rabbit antiserum raised against purified recombinant Scl1.41 protein P176 lacking 
the WM region detected the corresponding immunogen (lane 1), and the 
homologous full length protein in cell-wall extracts of MGAS6183 (lane 5) as well 
as MG1363::pSL230 L. lactis transformant (lane 4). This band was absent in cell-
wall extracts prepared from the WT L. lactis MG1363 (lane 2) and 
MG1363::pJRS525 transformant (lane 3). Expression of Scl1.41 at the cell 
surface was further established by flow cytometry. Rabbit anti-p176 antibodies 
stained Scl1.41 MG1363::pSL230 transformant, confirming the expression of 
Scl1.41 protein at the cell surface in the heterologous host L. lactis (Figure 5 C, 
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red trace). This protein was absent at the surface of WT MG1363 (black trace) 
and MG1363::pJRS525 transformant (green trace).  
 
The capacity of L. lactis expressing Scl1.41 to form biofilm was evaluated 
spectrophotometrically following crystal violet staining. As shown in Figure 5 D, 
the MG1363::pSL230 transformant demonstrated a significant increase in biofilm-
associated biomass at 24 h, as compared to wild type L. lactis or L. lactis-
containing pJRS525 vector (P ≤ 0.001). Crystal violet stained wells were 
photographed for visual representation of biofilm formation prior to 
spectrophotometric assay. Biofilm thickness and architecture were evaluated by 
CLSM (Figure 5E; Additional file 1: Figure S2 A-C). The MG1363::pSL230 
transformant produced a substantially thicker biofilm (14 m) as compared to 
both MG1363 WT (6 m) and the vector-only transformant MG1363::pJRS525 (6 
m). The MG1363::pSL230 cells formed highly aggregated structures, thus, 
acquiring a phenotype consistent with biofilm formation. As shown in Table 2, the 
MG1363::pSL230 transformant, expressing Scl1.41 surface protein, had 
significantly enhanced cell surface hydrophobicity (hydrophobicity index of 
~137% vs. 100% WT, P ≤ 0.001) with an actual value of 82.0 ± 2.6, when 
compared to the MG1363 WT (59.7 ± 7.2) and the vector-only 
MGAS1363::pJRS525 control (56.6 ± 5.5). These data suggest a direct 
relationship between Scl1 expression and cell surface hydrophobicity and 





Group A Streptococcus strains vary because of the vast number of M-protein 
types, and this variation is associated with varying frequency of isolation and 
exacerbation of disease (10, 67). The M41-, M28-, M3-, and M1-type strains 
selected for the current study represent a significant intraspecies diversity among 
clinical isolates of GAS. M41 GAS was a major causative agent of superficial skin 
infections (4, 5, 65), and strain MGAS6183, harboring the Scl1.41 protein, has 
been studied extensively (15-17). M28-type GAS (strain MGAS6143) has 
historically been associated with puerperal fever and currently is responsible for 
extensive human infections world-wide (30). M1T1 GAS, represented by strain 
MGAS5005, is a globally disseminated clone responsible for both pharyngitis and 
invasive infections (6, 7, 53). The M3-type strains of GAS cause a 
disproportionally large number of invasive GAS infections that are responsible for 
traumatic morbidity and death (41, 63).  
 
Initial studies by Lembke et al. that characterized biofilm formation among 
various M types of GAS typically included several strains of the same M type (19, 
43). These studies reported a significant strain-to-strain variation in ability to form 
biofilms within each M type. Studies that followed compared biofilm formation by 
defined isogenic WT and mutant strains to assess the contribution of specific 
GAS surface components responsible for a biofilm phenotype, including M and 
M-like proteins, hyaluronic acid capsule, lipoteichoic acid, and pili (22, 52). In the 
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current study, we have assessed the role and contribution of the surface protein 
Scl1 in the ability to support biofilm formation by GAS strains of four distinct M 
types. 
Recent advances in molecular mega- and pathogenomics has enabled the 
characterization of numerous M3-type strains with a single nucleotide resolution 
(8, 9). Interestingly, all five M3-type strains MGAS158, 274, 315, 335, and 1313 
that were originally used for scl1-gene sequencing (46), plus an additional strain 
MGAS2079 (not reported) harbor the same scl1.3 allele containing a null 
mutation that would result in secretion of a truncated Scl1.3-protein variant. Here, 
we demonstrate that these GAS strains do not form biofilm on an abiotic surface. 
Recently, bioinformatic screening of the sequences of ~250 invasive M3-type 
strains isolated globally, has led to the detection of this single nucleotide 
polymorphism that results in disruption of Scl1.3 protein (Steve Beres and Jim 
Musser, personal communication). Lembke et al. reported heterogeneous biofilm 
formation among four M3-type GAS strains examined over a 24, 48, and 72-hour 
period (43). Biofilm was detected for one strain at a 48 h time point, on a 
fibrinogen-coated surface; however, it is not known whether this clinical isolate 
forms biofilm on abiotic surface, whether it expresses the truncated or full-length 
Scl1.3 protein, and whether it produces an unknown fibrinogen-binding protein, 
which could augment the attachment and biofilm formation. Therefore, additional 
studies are necessary to define the contributions of other biofilm-formation 




Inasmuch as, variation in biofilm formation among GAS isolates of the same M-
type has been established, the molecular basis of this phenotypic variation is not 
known. Several GAS surface-associated and secreted components were shown 
to contribute to variation in biofilm (22, 25, 52). In addition, transcription 
regulators, such as Mga, CovR, and Srv are likely to play substantial roles in 
GAS biofilm formation (18, 25) due to their transcriptional regulation of numerous 
genes. Therefore, it is logical to assume that the combination of 
genomic/proteomic make up, allelic polymorphisms, and transcription regulation 
all contribute to this phenomenon. In addition, discrepancies between in vitro 
data obtained with laboratory-stored strains and microcolony formation in vivo 
likely exist and add yet another unknown to the complexity of GAS 
biofilm/microcolony formation and its role in pathogenesis. Despite this 
complexity, the analyses involving isogenic strains of the same genetic 
background provide valuable information that allows assessment of the role and 
contribution of a given GAS component to biofilm formation. 
The M1 MGAS5005 strain was shown to form biofilm in vitro and in 
experimental animals (20, 25, 62), and the present study demonstrates a 
significant role of Scl1.1 in this process. Likewise, the MGAS6183 strain, 
representing M41-type isolates often associated with pyoderma, produced a 
more robust biofilm biomass under the same experimental conditions and 
Scl1.41-deficient mutant was found to be an important determinant in this 
process. Similarly, Scl1.28 protein significantly contributes to a robust biofilm 
made by the M28-type strain MGAS6143. However, a recent study reported that 
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another surface protein, designated AspA, found in M28-type GAS significantly 
contributed to biofilm formation (50). The aspA isogenic mutant showed 60% 
reduction in biofilm formation. The strain MGAS6180, which they used, 
expresses the same Scl1.28 variant present in the MGAS6143 strain we used; 
our Scl1.28 mutant showed ~44% reduction in 24 h biofilm. We propose that 
several surface proteins contribute to biofilm formation by M28-type strains 
including proteins AspA and Scl1.28, and potentially, proteins F1/SfbI and F2 that 
are also present in these strains (16). This redundancy is likely responsible for 
the observed residual biofilms produced by the AspA- and Scl1.28-deficient 
mutants. 
The observed heterogeneity in biofilm architecture of different GAS strains 
was previously observed by Lembke et al. (43) and was also documented in the 
current study using FESEM. In addition, here we report the differences in GAS-
cell surface morphology and within cell-to-cell junctions in biofilms formed by M1- 
and M41-type strains. The structural and genetic determination of these 
differences is not known since M41 genome has not been sequenced, but may 
be associated with the presence of additional surface proteins, such as the F2 
protein (38) encoded by prtf2 gene found in this strain (16). Even more striking 
was an observed difference in the amount of the extracellular material associated 
with each strain, referred to as BAEM (bacteria-associated extracellular matrix). It 
has been shown that extracellular matrix, also called glycocalyx, is produced by 
biofilm-forming bacteria. DNA, lipids, proteins (25), polysaccharides and dead 
cell debris (12) were identified in this matrix and for gram-positive bacteria, 
69 
 
teichoic acids have also been detected (29, 54). The exopolysaccharide 
component of the glycocalyx is detected using carbohydrate-binding lectins, such 
as concanavalin A (ConA) (1). Both FESEM analysis and ConA staining detected 
more BAEM associated with M1 biofilm compared to M41, which produced larger 
biofilm. These observations suggest that GAS biofilm is stabilized differently by 
different strains and that higher BAEM production does not necessarily pre-
determine larger biofilm mass. Consequently, a combination of biofilm features 
rather than biofilm size alone may be more relevant to pathogenicity of a given 
GAS strain. 
Diminished adherence and biofilm formation could be associated with 
changes in cell surface hydrophobicity (21) of the scl1 mutants. Indeed, the lack 
of Scl1 resulted in both decreased hydrophobicity and the ability to form biofilm, 
albeit in a somewhat disproportionate manner. A decrease in the hydrophobicity 
index by only ~8%, as compared to the wild type-strain, was measured for the 
M41scl1 mutant and this modest decrease was accompanied by a rather large 
reduction in biofilm formation capacity after 24 h by 30%. Greater decrease in 
cell-surface hydrophobicity was measured for the M1scl1 (~21%) and M28scl1 
(~22%) mutants, which was accompanied by a significant loss in biofilm 
formation after 24 h by both isogenic strains by ~55% and ~41% (P ≤ 0.001 for 
each comparison), respectively. In addition, heterologous expression of Scl.41 in 
L. lactis increased hydrophobicity index of this organism to ~137% of the WT 
level, which was accompanied by significant increase in its ability to form biofilm. 
Similar observations have been reported for the M and M-like protein mutants 
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that typically, but not always, exhibit concurrent loss of both biological features 
(22). For example, isogenic Mrp49 mutant had a non-significant drop in 
hydrophobicity (~2%) but significantly lower biofilm formation after 48 h by ~30%, 
whereas Emm1 mutant lost ~78% hydrophobicity and ~44% biofilm formation 
capacity. In summary: (i) here we report that the Scl1 adhesin is also a 
hydrophobin with varying contribution to the overall surface hydrophobicity 
among GAS strains representing different M types and (ii) Scl1-associated 
surface hydrophobicity is likely to contribute to Scl1-mediated biofilm formation.  
To test whether Scl1 alone could support biofilm formation, we used a 
heterologous L. lactis strain, which provides an expression system for 
membrane-bound proteins of gram- positive bacteria with LPXTG cell-wall 
anchoring motifs (28, 44, 49, 59), including the group A streptococcal M6 protein 
(57, 58). In a recent study by Maddocks et al. (50) it was shown that 
heterologous expression of AspA GAS surface protein was able to induce a 
biofilm phenotype in L. lactis MG1363. We were also able to achieve a gain-of-
function derivative of the L. lactis WT MG1363 strain, (MG1363::pSL230), 
displaying an altered phenotype associated with biofilm formation, as compared 
to wild-type parental and vector-only controls. These data support our current 
model that Scl1 protein is an important determinant of GAS biofilm formation. 
As shown by crystal violet staining and CLSM, biofilm formation by the 
Scl1-negative mutants was compromised during the initial stage of adherence, as 
well as microcolony stabilization and maturation. Consequently, their capacity for 
biofilm formation as compared to the respective WT controls was greatly 
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reduced. This comparison identifies for the first time that the Scl1 protein 
contributes significantly to biofilm assembly and stability. Based on these 
observations, as well as previous work by us and others, we propose the 
following model of Scl1 contribution to GAS tissue microcolony formation (Figure 
6). First, the Scl1 hydrophobin (current study) initiates bacterial adhesion to 
animate surfaces within the host (21). Next, the Scl1 adhesin anchors the outside 
edge of growing microcolony in tissue by direct binding to tissue extracellular 
matrix components, cellular fibronectin and laminin (17). Microcolony 
development is stabilized by Scl1-Scl1 scaffolding resulting from Scl1’s capacity 
to form head-to-head dimers (68) between molecules located on adjacent chains. 
This model will be tested experimentally in future studies.  
 
Conclusions 
In the present work, using pathogenically differing GAS strains, we have 
demonstrated three concepts. First, we have confirmed previous observations 
that biofilm formation is an innate property of GAS strains. The M41-type strain 
used formed a more robust biofilm when compared to M28-type strain as well as 
M1-type strain. Importantly, the highly invasive M3-type strains devoid of the 
surface-associated Scl1 also lack the ability to form biofilm. Secondly, the 
absence of surface-associated Scl1 decreases GAS-cell hydrophobicity 
suggesting that Scl1 plays a role on the GAS surface as a hydrophobin. Thirdly, 
we have established that the Scl1 protein is a significant determinant for GAS 
biofilm formation. This concept was further tested by the heterologous expression 
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of Scl1 in Lactococcus, an organism found in dairy fermentation environments, 
enabling it to form biofilm. Altogether, these data underscore the importance of 
Scl1 in biofilm-associated regulation of GAS pathogenicity. Recently published 
work has shown that the recombinant Scl1 binds to the extracellular matrix 
components, cellular fibronectin and laminin (17). Our current research provides 
a foundation warranting additional investigation as to whether direct Scl1-ECM 
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Figures and Figure Legends  
 
Figure 1. Variation in biofilm formation among GAS strains.  
(A) Wild type M41-, M28-, M3-, and M1-type GAS strains were grown 24 h under 
static conditions and analyzed spectrophotometrically following crystal violet 
staining (top). Visual representation of corresponding wells is shown below.  (B) 
Schematic representation (not to scale) of Scl1.3 protein of M3-type GAS. 
Translated GXY repeats within the collagen-like (CL) region are shown with an 
asterisk representing the location of the premature stop codon resulting in a 
truncated protein. V, variable region; L, linker region; WM, wall-membrane 
associated region. Below, spectrophotometric measurements of 24-h biofilms 
following crystal violet staining are graphed for M3-type GAS strains. Absorbance 
values (OD600nm) are averages of at least three experiments done in triplicate 
wells. Corresponding confocal analyses of 24-h biofilms of MGAS315, 
MGAS2079, and MGAS158 are shown. Images are X-Y orthogonal Z-stack 






Figure 2. Field emission scanning electron microscopy of GAS biofilms. 24-
h biofilms of the M1- and M41-type GAS strains were grown on glass cover slips 
and analyzed by FESEM. (A-B) Architecture of GAS microcolonies shown at low 
magnification. (C-D) Cell surface morphology and cell-to-cell junctions observed 
















Figure 3. Production of bacterial-associated extracellular matrix. GFP-
expressing wild type (WT) M41- and M1-type GAS strains were grown on glass 
cover slips for 24 h and stained with TRITC-conjugated concanavalin A (ConA). 
Confocal laser scanning microscopic (CLSM) images were separated to 
represent green GFP-expressing GAS cells (left images) and red ConA-TRITC 
staining (right images) for detection of extracellular matrix associated with each 





Figure 4. Biofilm formation by wild type and scl1-inactivated isogenic 
mutants. Crystal violet staining and confocal laser scanning microscopy (CLSM) 
of the GFP-expressing GAS were used to compare biofilm formation by GAS 
strains. Wild type (WT) M41-, M28-, and M1-type strains, scl1-inactivated 
mutants (scl1), and M41 mutant complemented for Scl1.41 expression (M41 C) 
were used. (A-C) Isogenic GAS strains were grown under static conditions for 24 
h and bacterial biomass was detected spectrophotometrically at indicated time 
points following crystal violet staining. Absorbance values at OD600nm are 
representative of at least three experiments performed in quadruplicate. 
Statistical significance is denoted as *P ≤ 0.05 and **P ≤ 0.001. (D-F) CLSM 
analysis of corresponding 24 h biofilms from same experiment. Images are X-Y 
orthogonal Z-stack views of WT (top) and mutant (bottom) GAS strains. Views 
are representative of ten images within a single experiment. Average vertical 






Figure 5. Scl1 expression in L. lactis promotes biofilm formation. L. lactis 
was transformed with the plasmid construct pSL230 to express Scl1.41 surface 
protein or with pJRS525 vector. (A) PCR analysis of L. lactis transformants using 
scl1.41-gene-specific primers; lanes: (1) MG1363 wild-type (WT) cells; (2) 
MG1363::pJRS525 vector-only control; (3) MG1363::pSL230 transformant; (4) 
control pSL230 plasmid DNA. (B) Scl1.41 expression by western blot analysis of 
cell-wall extracts prepared from transformed L. lactis and control GAS strains 
using anti- P176 (rScl1.41) antibodies; lanes: (1) purified recombinant P176 
protein (truncated Scl1.41); (2) MG1363 WT strain; (3) MG1363::pJRS525 
vector; (4) MG1363::pSL230 transformant; (5) MGAS6183 (M41) control.          
(C) Analysis of Scl1.41 expression by flow cytometry with anti-P176 (rScl1.41) 
rabbit polyclonal antibodies on the surface of MGAS1363 WT strain (black trace), 
MGAS1363::pJRS525 vector-only control (green trace) and MG1363::pSL230 
transformant (red trace). (D) Crystal violet staining of 24 h biofilms formed by L. 
lactis WT strain, MG1363::pJRS525 vector-only control or MG1363::pSL230 
transformant (top) with visual representation of the corresponding wells (bottom). 
Statistical significance is denoted as **P ≤ 0.001. (E) CLSM analysis of 24 h 
biofilms from same experiment shown in (D). Images are X-Y orthogonal Z-stack 
views representative of ten images within a single experiment. Average vertical 




























Figure 6- Scl1-mediated model of GAS biofilm (not to scale). Scl1 
hydrophobin (current study) initiates bacterial adhesion to animate surfaces (21) 
within the host (blue field). Scl1 adhesin anchors the growing microcolony by 
direct binding to tissue extracellular matrix (ECM) components, cellular 
fibronectin and laminin (17), initiating microcolony formation and anchoring the 
outside edge of GAS microcolony in tissue (yellow field). Microcolony scaffolding 
is stabilized by the formation of head-to-head dimers between Scl1 molecules on 
adjacent chains (pink field). Inset shows Scl1-Scl1 head-to-head dimers formed 









Figure S1 (a). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
M41 wild type (WT) GAS biofilm at 24 h. Panels represent a gallery view of 
consecutive images taken at 1 micrometer increments. Panel shown in lower 
right corner represents an X-Y orthogonal Z-stack view (Fig. 4d). Thickness is 














Figure S1 (b). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
M41scl1 GAS biofilm at 24 h. Panels represent a gallery view of consecutive 
images taken at 0.75 micrometer increments. Panel shown in lower right corner 









Figure S1 (c). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
M28 WT GAS biofilm at 24 h. Panels represent a gallery view of consecutive 
images taken at 1 micrometer increments. Panel shown in lower right corner 













Figure S1 (d). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
M28Δscl1 GAS biofilm at 24 h. Panels represent a gallery view of consecutive 
images taken at 1 micrometer increments. Panel shown in lower right corner 










Figure S1 (e). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
M1 wild type (WT) GAS biofilm at 24 h. Panels represent a gallery view of 
consecutive images taken at 1 micrometer increments. Panel shown in lower 
right corner represents an X-Y orthogonal Z-stack view (Fig. 4f). Thickness is 












Figure S1 (d). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
M1scl1 GAS biofilm at 24 h. Panels represent a gallery view of consecutive 
images taken at 1 micrometer increments. Panel shown in lower right corner 










Figure S2 (a). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
Lactococcus lactis MG1363 wild type (WT) biofilm at 24 h. Panels represent a 
gallery view of consecutive images taken at 0.25 micrometer increments. Panel 
shown in lower right corner represents an X-Y orthogonal Z-stack view (5e). 








Figure S2 (b). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
Lactococcus lactis biofilm at 24 h. L. lactis was transformed with the shuttle 
vector pJRS525 (MG1363::pJRS525). Panels represent a gallery view of 
consecutive images taken at 0.25 micrometer increments. Panel shown in lower 
right corner represents an X-Y orthogonal Z-stack view (5e). Thickness is 














Figure S2 (c). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
Lactococcus lactis expressing Scl1.41 protein (MG1363::pSL230) biofilm at 24 h. 
L. lactis was transformed with the plasmid construct pSL230 encoding Scl1.41 
protein (MG1363::pSL230). Panels represent a gallery view of consecutive 
images taken at 0.5 micrometer increments. Panel shown in lower right corner 




Table 1. Cell surface hydrophobicity of GAS strains 
       GAS Strain                    M-Type            Actual Value†       Hydrophobicity Index‡  
MGAS6183 WT M41 92.6 ± .86 100  
MGAS6183 Δscl1 M41 85.2 ± 2.2 **92  
MGAS6183 Δscl1-C M41 98.0 ± .31 105  
MGAS5005 WT M1 80.3 ± .89  100  
MGAS5005 Δscl1 M1 63.3 ± 3.2  **79  
        MGAS6143 WT M28 94.3 ± .73 100 
MGAS6143 Δscl1 M28 72.6 ± .62 **78 
 
† 
Actual hydrophobicity values were calculated based on hexadecane binding as described in 
Methods. Values are representative of three separate experiments with ten replicates ±SD. 
‡
 Hydrophobicity Index represents the ration of actual hydrophobicity value for each strain to that 
of the isogenic wild-type (WT) strain multiplied by 100.  




Table 2. Cell surface hydrophobicity of Lactococcus strains 
Lactococcus Strain                                    Actual Value†      Hydrophobicity Index‡ 
L.lactis 1363 WT  59.7 ± 7.2 100 
L. lactis 1363::pJRS525  56.6 ± 5.5 98 
L. lactis 1363::pSL230  82.0 ± 2.6 **137 
 
† 
Actual hydrophobicity values were calculated based on hexadecane binding as described in 
Methods. Values are representative of three separate experiments with ten replicates ±SD. 
‡
 Hydrophobicity Index represents the ration of actual hydrophobicity value for each strain to that 
of the isogenic wild-type (WT) strain multiplied by 100. 
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Wounds are known to serve as portals of entry for group A Streptococcus (GAS). 
Subsequent tissue colonization is mediated by interactions between GAS surface 
proteins and host extracellular matrix components. We recently reported that the 
streptococcal collagen-like protein-1, Scl1, selectively binds the cellular form of 
fibronectin (cFn) and also contributes to GAS biofilm formation on abiotic 
surfaces. One structural feature of cFn, which is predominantly expressed in 
response to tissue injury, is the presence of a spliced variant containing extra 
domain A (EDA/EIIIA). We now report that GAS biofilm formation is mediated by 
the Scl1 interaction with EDA-containing cFn. Recombinant Scl1 proteins that 
bound cFn also bound recombinant EDA within the C-C’ loop region recognized 
by the 91 integrin. The extracellular 2-D matrix derived from human dermal 
fibroblasts supports GAS adherence and biofilm formation. Altogether, this work 
identifies and characterizes a novel molecular mechanism by which GAS utilizes 
Scl1 to specifically target an extracellular matrix component that is predominantly 
expressed at the site of injury in order to secure host tissue colonization.  
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Group A Streptococcus (GAS) is responsible each year for more than 730 million 
infections world-wide ranging from the clinically uncomplicated (pharyngitis, 
impetigo) to severe and invasive diseases (necrotizing fasciitis, toxic shock), and 
autoimmune complications (9, 81). GAS causes over 100 million skin infections 
and is categorized as transient or contaminant flora of the skin (85). These 
infections are initiated via a portal of entry resulting from simple skin 
infringements, such as insect bites or cuts and scratches, as well as from more 
serious postsurgical wounds. For successful colonization within a wounded site, 
GAS utilizes surface adhesins to secure binding to host extracellular matrix 
(ECM) components (14), including collagen, fibronectin (Fn) and laminin.  
 The streptococcal collagen-like protein-1 (Scl1) is a ubiquitous surface 
adhesin, which is co-expressed with a range of known virulence factors that are 
regulated by the multiple virulence gene regulator of GAS (Mga) (2, 49, 50, 67). 
Scl1 is a homotrimeric protein protruding from the GAS surface that contains four 
structurally distinct regions. The outermost N-terminal variable (V) region is 
adjacent to a collagen-like (CL) region that consists of a varying number of 
GlyXaaYaa (GXY) repeats and adopts stable collagen-like triple helices (57, 87). 
At the C-terminus, Scl1 contains a linker (L) region which is a series of 
conserved, direct repeats adjoining the CL region to the cell wall/membrane 
(WM)-associated region. Functionally, Scl1 was shown to bind to host-cell 
integrin receptors (10, 11, 36) and plasma components (26, 29, 62). We recently 
reported that Scl1 selectively binds to cellular fibronectin (cFn), but not plasma 
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fibronectin (pFn) (13). Scl1 is also recognized to play a significant role in biofilm 
formation on abiotic surfaces (60). 
 The wound healing process is dependent on the interaction of cells with the 
surrounding ECM, which induces the formation of an ECM scaffold to promote 
cell migration and wound closure. A fundamental component within the ECM 
contributing to this process is cFn (56). The fibronectins form a large 
heterogeneous group of glycoproteins with isoforms resulting from alternative 
splicing events of pre-mRNA of a single gene (64). The soluble pFn is 
predominantly produced by hepatocytes, whereas cFn can be produced by 
diverse cell types and may generate up to 20 isoforms in humans. It contains 
varying amounts of two extra domains termed EDA (EIIIA) and EDB (EIIIB). 
EDA- and EDB-expressing cFn is highly regulated and plays a crucial role during 
embryogenesis and early development, and under non-diseased states is 
maintained at low levels within tissue of adult humans. The expression of cFn 
containing EDA (EDA/cFn) is upregulated during tissue repair and likely 
promotes wound cell function by the direct binding of 41, 47, and 91 
integrins (25, 35, 42, 46, 71, 77, 84). 
 In this work, we characterized the Scl1-cFn interaction using recombinant Scl 
proteins (rScl) derived from epidemiologically distinct GAS strains and 
investigated the significance of this binding during GAS biofilm formation. We 
report that Scl1 protein selectively targets the EDA domain of cFn, which is 
expressed during tissue repair. We mapped the Scl1 binding site within the C-C’ 
loop region of EDA using peptide inhibition and antibody blocking assays, which 
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overlaps with the EDA-91-integrin-binding site. Furthermore, the Scl1-ECM 
binding contributes significantly to GAS biofilm formation, which can be inhibited 
by either the treatment with the synthetic C-C’ loop peptide or with the anti-EDA 
mAb, IST-9. In conclusion, this work identifies a novel cFn binding mechanism, 
which is conserved among pathogenically varying strains of GAS, and is 
mediated by Scl1 binding to the EDA/cFn variant that is expressed at the portal 
of pathogen entry. The Scl1-EDA/cFn binding may extend the time for GAS 




The Scl1-cFn interaction is mediated by the EDA domain of cFn  
In a previous study, we established that the Scl1 protein selectively binds the 
tissue extracellular matrix component, cFn (Fig. 1A) but not pFn (13). Based on 
this finding, we hypothesized that the Scl1-cFn interaction is mediated via EDA, a 
domain that is not found in plasma fibronectin, but is thought to be an integral 
component to the wound healing process. To test this hypothesis, we evaluated 
by direct ELISA the binding of ECM ligands to immobilized rScl1 proteins P176 
(Scl1.41), P144 (Scl1.1), and P161 (Scl1.28) that were previously demonstrated 
to bind cFn (13). An immobilized rScl2 construct, P163 (Scl2.28), served as a 
negative control for cFn binding. The ECM ligands (1 g/well) tested included: (i) 
purified cFn as a positive control, and confirmed to contain the EDA/cFn variant 
using the EDA-specific mAb IST-9, (ii) the rEDA, and (iii) the recombinant type III 
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domain four (rIII4), which differs by primary sequence but is structurally 
homologous to EDA and is common to both cFn and pFn. As shown in Fig. 1B, 
rScl1 proteins that are positive for cFn binding are also positive for binding to 
rEDA. In contrast, binding of the rIII4 to rScl1 proteins was comparable to that of 
the negative control, P163, for all three ECM ligands. When increasing 
concentrations (0.02 - 4.0 M) of ECM ligands cFn, rEDA and rIII4 were 
incubated with immobilized rScl proteins to assess binding specificity, 
concentration-dependent binding of cFn and rEDA to all three rScl1 constructs 
was observed, plateauing around the 3-4 M concentration (Fig. 1C). In contrast, 
no binding by rIII4 to rScl1 constructs was observed over the entire concentration 
range nor was binding by any ECM ligand to the negative control, P163, detected 
(data not shown). We also observed that rScl1 proteins bind better to cFn than 
rEDA construct. One possible explanation is that the EDA conformation in cFn 
and rEDA preparations is not identical or that rScl1 binding alters cFn structure 
(53), resulting in improved binding. The latter mechanism would not be surprising 
since it has been reported for Fn binding by other bacterial adhesins, including 
streptococcal (M, F1/SfbI) and staphylococcal (FnbpA) proteins, as well as the 
BBK32 protein of Borrelia burgdorferi (21, 34, 40, 55). Altogether, our data 
indicate that the Scl1-cFn interaction is mediated, at least in part, via the EDA 






Mapping of Scl1 binding site within EDA 
The cFn/EDA spliced variant produced in response to tissue injury (8, 25, 74, 77) 
includes a loop region between the C and C’ -strands (Fig. 2A), which mediates 
binding to 41 and 91 integrins that actively participate in wound healing (75). 
Since loop regions are often involved in protein-protein interactions, we 
hypothesized that the C-C’ loop region of EDA contains the Scl1 binding site. To 
test this, we examined the ability of an exogenous synthetic eleven amino-acid 
peptide (TYSSPEDGIHE), corresponding to the C-C’ loop region of EDA, to 
inhibit binding of ECM ligands to immobilized rScl1 proteins, P176, P144, and 
P161. In this assay, increasing concentrations (0.01 mM, 0.1 mM, and 1.0 mM) 
of the C-C’ loop peptide or a scrambled peptide control (SEDIHYTEGPS) were 
pre-incubated with immobilized rScl proteins prior to the addition of the ECM 
ligands, cFn and rEDA. As shown in Fig. 2B, binding of cFn or rEDA to all three 
rScl1 proteins was inhibited by the C-C’ loop peptide in a concentration-
dependent manner up to 50% and 60% respectively, whereas no inhibition was 
observed with the scrambled peptide. These results mapped a Scl1 binding site 
to the EDA C-C’ loop region.  
 Previous studies reported that residues Asp41 and Gly42 (Fig. 2A) within the C-
C’ loop region of EDA are involved in 91-integrin binding and that the 
monoclonal antibody IST-9 binds the C-C’ loop of EDA at adjacent residues Ile43 
and His44, and blocks this integrin engagement (47, 75). We therefore used the 
anti-EDA mAb IST-9 to determine if Scl1 and 91 integrin have overlapping 
binding sites within the EDA C-C’ loop region (Fig. 2C). Both cFn and rEDA were 
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pre-treated with increasing concentrations (0.1 g, 1.0 g, and 10 g) of IST-9 
before mixtures were added to and incubated in the wells with immobilized rScl1 
proteins. With increasing concentrations of IST-9 mAb, we show a significant 
inhibition of binding by both cFn (10-45%) and rEDA (20-54%) to all three rScl1 
constructs. These data mapped a Scl1 binding site within the C-C’ loop region of 
EDA, which is also recognized by the 91 integrin.  
 
The rScl1-EDA interaction represents a common cFn-binding mechanism among 
pathogenically varying GAS strains  
Previous work showed that Scl1 and Scl2 proteins are related but differ in their 
CL region length and type of triplet repeats used (30, 87). Likewise, phylogenetic 
tree of the Scl1- and Scl2-V regions revealed that they form two separate 
branches but are evolutionary related (29). The V-region sequences also differ 
among Scl1 and Scl2 variants found in various GAS strains and they are typically 
M-type specific (49, 50, 66, 67, 86). To date, majority of human ligands bind to 
Scl1-V but not Scl2-V regions and they display two main binding patterns e.g., 
some bind factor H (CFH) and factor H-related protein 1 (CFHR1)(12, 68), 
whereas other bind low-density lipoprotein (29) and ECM components, cFn and 
Lm (13). To test whether cFn binding via EDA was conserved among Scl1 
variants originated from GAS strains of various M types, we examined all 
previously tested rScl constructs (12) for binding to rEDA. In this assay, we used 
the rScl1 proteins, including P144, P161, P176, P186, P190, and P217 that were 
positive for binding to cFn and Lm, as well as the CFH/CFHR1-binding positive 
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rScl1 proteins P179 and P216. In addition, the rScl2 proteins P163, P177, and 
P178 were used as ligand-binding negative controls. As shown in Fig. 3A, rScl1 
binding to cFn corresponded with binding to rEDA, whereas no binding to pFn by 
any rScl1 or rScl2 proteins was observed. To test whether all rScl1 constructs 
bind EDA via the same mechanism, we examined binding of cFn and rEDA in the 
C-C’ peptide inhibition assay described above. The C-C’ loop peptide was able to 
compete with both cFn and rEDA binding to rScl1 proteins, decreasing binding by 
50-70%, with no inhibition detected by the scrambled peptide (Fig. 3B). As 
expected, no additional binding inhibition was observed by the C-C” loop peptide 
for cFn- and rEDA-binding negative rScl1 and rScl2 proteins. Peptide inhibition 
results were further strengthened by the IST-9 antibody blocking assay, which 
was also found to inhibit binding of cFn and rEDA 50% and beyond. The data 
provide evidence that cFn binding via the C-C’ loop region of EDA is conserved 
among pathogenically varying GAS strains expressing the ECM-binding Scl1 
variants.  
 
The Scl1-ECM interaction supports GAS biofilm formation  
Scl1 proteins have been found to mediate GAS biofilm formation on an abiotic 
surface (60). To assess the importance of the Scl1-cFn interaction in GAS biofilm 
formation, cell biomass produced by three epidemiologically diverse M41-, M28-, 
and M1-type GAS strains was compared spectrophotometrically following crystal 
violet staining in an early adhesion (1 h) and mature biofilm (24 h) in untreated or 
cFn-treated wells (Fig. 4A). M41 wild-type (WT) and the available M41scl1-
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complemented (scl1-C) mutant strains form a more robust biofilm at 24 h (O.D.600 
~0.5 untreated vs. ~0.7 cFn-coated), as compared to M28 WT (~0.45 untreated 
v. ~0.6 cFn-coated) and M1 WT (~0.23 untreated; ~0.34 cFn-coated) strains. 
Importantly, in each case, more bacterial biomass was detected in cFn-treated 
wells than on abiotic surface during both the early adherence stage (1 h), as well 
as in mature biofilms (24 h). Finally, we show a statistically significant decrease 
in biofilm forming capacity by all Scl1-negative isogenic mutants as compared to 
their parent strains at both time points. Confocal laser scanning microscopy 
(CLSM) of 24 h biofilms confirmed crystal violet staining results (Fig. 4B). The 
M41 WT biofilm was the most robust with a thickness averaging 26 m, while a 
nearly 50% decrease was observed for the M41scl1 mutant (15 m). A similar 
pattern is shown for the M28 WT (22 m) over the scl1 mutant (14 m). The M1-
type WT GAS (15 m) has a decreased capacity for biofilm formation with 
M1scl1 mutant (7 m) poorly supporting a biofilm phenotype. When compared to 
GAS biofilms formed in untreated (abiotic) wells by the same strains (60), cFn-
mediated biofilms were enhanced up to 40% in average thickness recorded for 
wild-type strains. Collectively, we can conclude from these studies that Scl1-
mediated binding of GAS to cFn significantly enhances biofilm formation.  
 
Scl1-mediated binding to fibroblast-derived ECM supports GAS adherence and 
biofilm formation  
To develop a system that allows biofilm development on ECM more closely 
mimicking the ECM in tissue in vivo, normal human dermal fibroblasts (HDFa) 
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were used to deposit extracellular matrix. To generate the fibroblast-derived ECM 
(fdECM), wells were denuded of HDFa cells and the presence of fdECM was 
visualized by Ponceau S staining (Fig. S1A). When the composition of fdECM 
coating was characterized by ELISA using antibodies that detect ECM proteins, 
fibronectin and collagens were identified as major constituents (Fig. S1B). 
Importantly, we detected the presence of the EDA/cFn variant within fdECM 
using the monoclonal antibody, IST-9. Thus, we confirmed that fdECM coating 
provides a more complex model of tissue matrix compared to single ECM 
component, which includes the EDA/cFn population recognized by Scl1, a 
streptococcal adhesin.   
 GAS strains used in this study express varying numbers of surface adhesins, 
including fibronectin-binding adhesins. The fdECM matrix contains a number of 
ECM components assembled into a higher-ordered structure more suitable for 
assessing whether Scl1-EDA/cFn binding significantly contributes to the 
adherence and biofilm formation by epidemiologically varying GAS strains. The 
structural complexity of the fdECM network was demonstrated by field emission 
election microscopy (FESEM) (Fig. 5A, row (i)). Using FESEM to image GAS 
adherence on a fdECM coating, wild-type GAS strains of M1- (ii), M28- (iii), and 
M41-type (iv) were observed to be targeted or preferentially bound to fdECM 
deposits, as compared to the surrounding abiotic surface at early time points in 
infection. At higher magnification, GAS chains are observed in close contact with 
fdECM fibrous structures. When GAS WT and scl1-inactivated mutant strains 
were compared based on crystal violet staining for bacterial biomass after 1 h 
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(adherence) and 24 h (mature biofilm) on fdECM, or cFn-coated wells, GAS-
fdECM binding produced comparable biofilm absorbance values to those of the 
cFn-treated wells (Fig. 5B). Scl1-negative isogenic mutants had decreased 
capacity for adherence and mature biofilm formation, as compared to their WT 
parent strains, on both ECM-treated wells. Our findings demonstrated that the 
Scl1 protein plays a significant role in GAS biofilm formation on a single cFn 
coating, as well as on a more complex fdECM, for all strains tested.  
 Experiments shown in Figs. 2-3 demonstrated that we can significantly inhibit 
rScl1 binding to both rEDA and cFn using the synthetic C-C’ loop peptide or IST-
9 mAb. Here, we adapted both inhibition assays in order to evaluate the 
importance of the interactions between native Scl1 surface protein and EDA/cFn 
component of fdECM in total GAS adherence (Fig. 6). Graphs represent 
spectrophotometric measurements following crystal violet staining (OD600 values) 
obtained for each WT strain (M41, M28, and M1) on all three ECM coatings (cFn, 
rEDA, fdECM) in wells without inhibitors and in wells treated with either the C-C’ 
loop peptide (panel A) or IST-9 mAb (panel B). Below the graphs, we present 
these OD600-values data as percent (%) adherence inhibition, as compared with 
their corresponding untreated samples (100% adherence). For comparison, we 
also present % adherence inhibition, resulting from genetic inactivation, of their 
corresponding untreated scl1 mutants (OD600 values are shown in Fig. S2). First, 
the C-C’ loop or scrambled peptide (1 mM each) were added to GAS WT (Fig. 
6A) or scl1 mutant strains (Fig. S2A). Next, peptide-GAS mixtures were added to 
ECM-coated wells and 1 h adherence was analyzed spectrophotometrically 
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following crystal violet staining. The adherence of all WT strains was significantly 
inhibited on all three coatings, whereas adherence of scl1-inactivated mutants 
was unaffected by peptide treatment (Fig. S2). Inhibition levels of adherence 
obtained for peptide-treated strains type M41 and M28 were similar, ranging on 
assorted ECM coatings between 25 - 27% of their untreated samples. The 
remaining binding levels (as well as % inhibition values) were similar to the 
binding levels of untreated Scl1-negative mutant strains, ranging between 24 – 
28%, which is depicted in the graph by horizontal lines over-imposed on bars 
representing untreated samples. Interestingly, a 25-33% C-C’ peptide inhibition 
range was also measured for the M1 WT strain; however, the binding-inhibition 
levels obtained for the M1-scl1 mutant on assorted ECM coatings were 
substantially higher (51-54%). No strains were inhibited by treatment with the 
scrambled peptide (data not shown).   
 In a second set of inhibition studies (Fig. 6B, Fig. S2B), ECM-coated wells 
were pre-treated with 10g of mAb IST-9 for 1 h followed by the addition of GAS 
strains. Again, 1 h adherence was analyzed spectrophotometrically following 
crystal violet staining. Similar to the peptide inhibition described above, we 
identified a statistically significant decrease in adherence by M41 and M28 WT 
strains treated with IST-9 mAb (24-30% range) and, again, the remaining binding 
levels of these IST-9-treated samples were similar to the binding levels of their 
untreated Scl1-negative mutants (25-32%). As previously shown, by comparison, 
the M1 scl1 mutant had substantially decreased adherence on all three ECM 
coatings (50-60% inhibition), whereas adherence inhibition of the M1 WT strain 
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due to IST-9 treatment was lower (32-35%). In total, inhibition studies 
demonstrate that GAS adherence to ECM substrates, including complex fdECM 
network, can be abrogated with treatments that target the integrin-binding C-C’ 
loop region of the EDA/cFn.  
 
Discussion  
The skin is an organ covering the human body that forms an effective barrier 
between the internal and external environments and protects against invading 
microbes (33). Group A Streptococcus (GAS) is, together with Staphylococcus 
aureus, a predominant pathogen of the skin and soft tissue (7, 85). GAS, as well 
as other bacteria, requires a portal of entry to initiate the infection. In the 
wounded site, GAS faces a new environment, which creates a unique opportunity 
for adhesion to the host’s cellular and extracellular components via surface 
adhesins designated MSCRAMMs for ‘microbial surface components recognizing 
adhesive matrix molecules (65). Among various MSCRAMMs expressed by GAS 
strains (14), Scl1 was recently shown to selectively bind cFn (13). Here, we 
characterize Scl1-cFn interactions and investigate the role of this binding in GAS-
ECM adherence and biofilm formation on single ECM coatings and on complex 
ECM structures deposited by human cells.  
 In the present study, we selected three model GAS strains representing the 
intraspecies breadth. The M1-type strain represents the global M1T1 clone 
responsible for pharyngitis and invasive infections (4, 78), the M28-type strain 
has been historically associated with puerperal sepsis (27, 28, 58), and the M41-
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type strain has been predominantly linked to skin infections (3, 22, 23). 
Importantly, these strains vary in the number of fibronectin (Fn)-binding proteins 
they express in addition to Scl1 (10). The M28-type strain harbors at least three 
genes encoding known Fn-binding proteins, including the serum opacity factor 
(sof) (17, 39, 59), prtF1/sfbI (31) and prtF2/pfbp (37, 70). M41-type strain has the 
prtF2/pfbp gene, whereas the M1-type strain has none of them. Based on this 
knowledge, the contribution of each Scl1.1, Scl1.28, and Scl1.41 variant to the 
attachment and biofilm formation on single cFn and complex fdECM coatings by 
these strains was tested.  
 First, we investigated the selective recognition of and binding to cFn by rScl1 
proteins. There is a large body of literature describing redundancy in Fn binding 
by GAS surface proteins (32). They are often closely related among Gram-
positive bacteria or contain related regions that are involved in Fn binding (65) 
and include GAS proteins M, F1/SfbI, SfbII, F2/PFBP, SOF, FBP54, and FbaA 
and B (6, 17, 21, 37, 43, 44, 79, 82, 83). Unlike Scl1, these proteins bind pFn and 
subsequent studies mapped their binding sites within the N-terminal region 
spanning type I and type II repeats of Fn, which is identical in pFn and cFn (18, 
24, 54, 61). The cFn isoforms differ from pFn in that they include in varying 
proportions the extra domains, termed EDA/EIIIA and EDB/EIIIB (64). In the 
wound, platelets are activated, degranulate and release EDA-containing Fns into 
the apical aspect of the fibrin matrix in the region that is first encountered by 
microorganisms (71). Within two days wound macrophages and fibroblasts 
produce cFns rich in the EDA segment and these cFns persist throughout the 
113 
 
wound bed for at least a week following injury (8). Using peptide inhibition and 
antibody blocking experiments, we demonstrated that multiple rScl1 proteins bind 
cFn via the C-C’ loop region of EDA, indicating a common binding mechanism 
among pathogenically discrete strains. Thus, we have identified a novel Fn-
binding mechanism unique to Scl1, which allows GAS to target the EDA/cFn 
spliced variant expressed in wounded tissue.  
 Within hours of injury, neutrophils populate the wound and thereafter 
macrophages arrive and epidermal keratinocytes commence migration over the 
provisional matrix (56). These cells express integrins that bind the EDA/cFn, 
including 91 (80). The C-C’ loop region of EDA domain mediates binding to 
91 and 41 integrins (Shinde and Van De Water, unpublished observations) 
and has been shown to participate in cell adhesion, cell spreading (75) and 
matrix assembly (5). Aberrations in, or blocking of, the C-C’ loop region in EDA 
abrogates the EDA-integrin binding (46, 75). Our current binding-inhibition 
studies, as well as preliminary cell-attachment inhibition assays (not shown), 
demonstrated that rScl1 binds to the C-C’ functional loop region of EDA, which is 
also the integrin-binding site. This implies that during GAS infection, the Scl1 
adhesin could abrogate human cell migration and adhesion, thus, impairing 
wound healing. Interestingly, a recent study showed that reepithelialization of a 
murine cutaneous wound was delayed by staphylococcal infections (72). 
Considering the overall similarities between streptococcal and staphylococcal 
skin infections, it is tempting to speculate that GAS evolved analogous molecular 
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mechanisms that augment tissue colonization by manipulating the local host’s 
environment at the site of infection.   
 GAS biofilm is a relatively new concept (45), which is increasingly being 
established with supporting data collected from clinical specimens (1) and 
through animal model research (16, 69). Several GAS surface components have 
been reported to participate in biofilm formation (15, 19, 41, 51, 52) including the 
Scl1 protein (60). In the latter study, we reported that Scl1 plays a substantial 
role in GAS biofilm formation on an abiotic surface. We also proposed a model in 
which Scl1-ECM binding enhances biofilm formation by anchoring the growing 
biofilm structure. Here, we tested that model by assessing the significance of one 
interacting component, Scl1-cFn binding in the formation of GAS biofilm. Direct 
comparison of biofilms grown by the M1-, M28-, and M41-type strains showed a 
significantly increased biofilm biomass on cFn-coated surface compared to an 
inanimate surface. These differences were further confirmed microscopically 
since the average thickness of mature biofilms formed by each of these strains 
was higher on cFn coating by up to 40%. However, these results could also be 
explained by the non-Scl1-mediated interactions between cFn and other Fn-
binding MSCRAMMs expressed by these strains. Therefore, a similar 
comparison was made between biofilms formed by the wild-type and isogenic 
scl1-inactivated mutants of each M-type strain on cFn coating. Despite the 
presence of additional Fn-binding proteins, especially in M28- and M41-type 
strains, that bind a different region of Fn, all Scl1-devoided mutants produced 
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significantly lower biofilm biomass and lower biofilm thickness by nearly 50%, 
suggesting an important role for the Scl1-EDA interaction.  
 The complexity of natural ECM in tissue exceeds the single cFn coating we 
initially employed. Therefore, we developed a more complex fibroblast-derived 
ECM coating (fdECM), which was denuded of cells. Following eukaryotic cell 
removal, tissue culture wells contained a complex 2-D fibrillar network composed 
of several ECM components, including various collagens and laminin in addition 
to the EDA/cFn isoforms within fibronectin. A similar approach was used to study 
the attachment and biofilm formation of Klebsiella pneumoniae on coating 
derived from ECM deposited by bronchial epithelial cells (38). This coating 
produced a rich biofilm phenotype that was more versatile as compared to a 
collagen coating or an abiotic surface. In our hands, complex fdECM supported 
wild-type GAS adherence and biofilm formation at the levels comparable with 
cFn coating. Scanning electron microscopy revealed targeted or preferential GAS 
binding to fdECM structures over the surrounding abiotic area. The scl1 isogenic 
mutants showed significantly decreased adherence and biofilm formation on 
fdECM similarly to that on cFn-treated wells. Furthermore, we were able to 
reduce the adherence of the wild-type strains to the levels shown by the scl1 
mutants with the C-C’ loop peptide and mAb IST-9. The importance of Scl1-
EDA/cFn binding in GAS adherence on fdECM was intriguing considering the 
fact that GAS cells are equipped with more than one Fn-binding protein and, 
likely, with more than one type of MSCRAMM targeting additional components of 
fdECM. Since inhibition was not complete, our data also point at the contribution 
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and importance of other adhesins and alternative ECM-binding mechanisms to 
GAS adherence and host colonization.  
 In summary, we characterized Scl1-cFn interactions and mapped the Scl1 
binding site within the functional C-C’ loop region of the EDA segment 
overlapping with the 91-integrin binding site. This observation opens new 
directions of investigations since 91 is expressed by a number of epithelial and 
inflammatory cells involved in tissue repair and wound healing (63, 76, 77, 80). 
We studied the contribution of Scl1-ECM adhesion in GAS biofilm formation on a 
single cFn coating and on complex fdECM 2-D matrix. Based on these results, 
we propose a model of the Scl1-mediated tissue colonization by GAS (Fig. 7). In 
this mechanistic model, the opportunistic GAS pathogen exploits injured tissue 
as a portal of entry to establish skin infection. Within injured site, platelets, 
macrophages, and underlying injured fibroblasts deposit in the wound bed a 
provisional ECM matrix (proECM), which includes the EDA-enriched cFn to 
provide scaffolding for cell migration and proliferation via 91,  and 
integrins, and promote structural remodeling and tissue repair (35). Upon 
entry into the injured site, GAS utilizes the Scl1 protein to initiate binding to the 
EDA domain of cFn, which is mediated via the C-C’ loop region and secures 
adherence to ECM, facilitating microcolony formation. Scl1 acts in concert with 
other GAS adhesins that, depending on strain, may include Fn-binding proteins 
M, F1/SfbI, SfbII, F2/PFBP, SOF, FBP54, and FbaA and B (6, 17, 21, 37, 43, 44, 
47, 73, 79, 82). The Scl1-EDA binding may also compete with EDA binding by 
the integrins expressed on migrating keratinocytes, thus, delaying wound 
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reepithelialization and healing. Growing GAS microcolonies form a focused nidus 
of tissue infection until it is overcome by immune defenses or disperses to new 
superficial or deep tissue sites. Validation of this updated model is ongoing 
research.  
 
Experimental procedures  
Bacterial strains and growth  
The M41- (MGAS 6183), M28- (MGAS 6143), and M1-type (MGAS 5005) strains 
of group A Streptococcus were used. All GAS cultures were grown at 37oC in an 
atmosphere of 5% CO2–20% O2. For biofilm formation, GAS strains were grown 
overnight on brain-heart infusion agar (BHI) (BD Biosciences) and used to 
inoculate Todd-Hewitt broth (Difco) supplemented with 0.2% yeast extract (THY 
medium). Cultures were incubated until they reached logarithmic phase (O.D. 600 
~0.5) and used to inoculate treated or untreated tissue culture wells.  
 
Construction of scl1-inactivated mutants 
The isogenic Scl1-negative mutants for all wild-type strains were constructed by 
allelic replacement as described previously. Briefly, the scl1 gene in M1-type 
strain was inactivated using the suicide plasmid, pSL134, harboring the scl1.1 
allele with flanking regions and nonpolar spectinomycin resistance cassette, 
spc2, inserted in-frame to replace the scl1.1 coding region (48). The scl1.28 and 
scl1.41 alleles were inactivated using the pSL170 suicide plasmid containing the 
erythromycin resistant scl1.28::erm2 construct (10, 29). Wild-type strains were 
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electroporated followed by incubation in THY medium for 2.5 hours. Cultures 
were then plated onto BHI agar containing either 100 g ml-1 of spectinomycin or 
3 g ml-1 of erythromycin. Drug-resistant transformants were initially screened by 
PCR for amplified single products, indicating double cross-over recombination, 
and were subsequently confirmed by DNA sequencing. For complementation of 
the scl1.41-inactivated mutant, the MGAS 6183 scl1-mutant cells were 
electroporated with the plasmid construct pSL230 encoding the Scl1.41 protein 
(10). Scl1 expression or lack of it was confirmed by western immunoblotting.  
 
 
Recombinant proteins  
Several scl1 and scl2 alleles encoding the extracellular protein portion were 
amplified by PCR and cloned into the pASK-IBA2 vector designed for periplasmic 
protein expression (10, 29, 30, 36, 87). Recombinant Scl1 and Scl2 (rScl) 
proteins used in these assays: P144/rScl1.1 (accession no. AF252861), 
P161/Scl1.28 (accession no. AY459361), P176/rScl1.41 (accession no. 
AY452037), P179/rScl1.6 (accession no. EU 127997) P186/rScl1.12 accession 
no. DQ309441), P190/rScl1.2 (accession no. EU127996), P216/rScl1.55 
(accession no. EU127999), P217/rScl1.52 (accession no. EU127998), 
P163/rScl2.28 (accession no. AY069936), P177/rScl2.4 (accession no. 
DQ309442), P178/rScl2.77 (accession no. DQ309443). All recombinant Scl 
proteins contain short C-terminal tag, the Strep-tag II (WSHPQFEK), which has 
high binding affinity to Strep-Tactin-Sepharose for affinity chromatography 
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purification (IBA-GmbH, Goettingen, Germany). E. coli DH5 and BL21 strains 
were used for cloning and protein expression, respectively. 
 The his-tagged recombinant EDA (rEDA) and III4 (rIII4) polypeptides were 
prepared as described (47). Briefly, EDA or III4 cDNA was amplified by PCR, 
cloned into plasmid pGEX-2T, expressed in E. coli, and purified using affinity 
chromatography nickel columns.  
 
Protein binding assays 
For binding studies, rScl proteins (0.5 M) were immobilized onto Strep-Tactin-
coated microplate wells for 1.5 h at room temperature and blocked with Tris-
buffered saline (TBS) supplemented with 1% bovine serum albumin (BSA) 
overnight at 40C followed by incubation with the extracellular matrix (ECM) 
proteins cellular fibronectin (cFn), rEDA, and rIII4 or plasma fibronectin 
(pFn)(Sigma). The no rScl controls were performed in BSA-coated wells for each 
ligand and each antibody used. Final ODs were normalized by subtracting the 
BSA controls in each experimental setup.  
 All ECM ligands prepared at 0.25 M concentration for binding inhibition 
studies or 1 g of ECM ligand per well for protein screening experiments, were 
added to rScl-immobilized wells in triplicate and incubated at room temperature 
for 1 h. Bound ligands were detected with specific anti-cFn (Sigma) and anti-
collagen I, -collagen II, -collagen IV primary antibodies and goat-anti-rabbit 
secondary antibodies conjugated to horseradish peroxidase (HRP)(BioRad). The 
120 
 
HRP substrate, 2,20-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) was used 
and colorimetric reaction was recorded at O.D. 415 nm.  
 For peptide inhibition studies, synthetic 11-amino-acid peptide representing 
the C-C’ loop region of the EDA domain (TYSSPEDGIHE) or a scrambled loop 
peptide (SEDIHYTEGPS) were used (LifeTein, Inc.). rScl proteins (0.5M) were 
immobilized onto Strep-Tactin-coated wells as above and were either untreated 
or were pre-incubated with increasing concentrations (0.01-1.0 mM) of the 
synthetic C-C’ loop EDA peptide or scrambled peptide for 30 minutes to 1 h at 
room temperature. cFn or rEDA ligands were next added to the wells and 
incubated at room temperature for 1 h. Bound ECM ligands were detected with 
specific primary and HRP-conjugated secondary antibodies as above.  
 For antibody inhibition studies, the monoclonal antibody IST-9 was used, 
which recognizes the Ile43 and His44 epitope (47) within the C-C’ loop region of 
EDA. ECM ligands (0.25 M) were pre-incubated with increasing concentrations 
(0-10 g) of the IST-9 mAb for 30 minutes at room temperature. Mixtures were 
added to rScl1-immobilized wells and bound ECM ligands were detected as 
above with specific primary and HRP-conjugated secondary antibodies.  
 
Analysis of biofilm formation 
Crystal violet staining assay. Untreated or pre-treated tissue culture polystyrene 
24-well plates were used to assess biofilm formation. ECM-coated wells were 
pre-treated with cellular fibronectin, rEDA or 1% BSA in TBS overnight at 4oC 
and then blocked for 2 h with 1% BSA in TBS at room temperature. Exponential-
121 
 
phase GAS cultures (0.5 ml) were seeded into untreated or treated wells and 
incubated at 37oC in an atmosphere of 5% CO2–20% O2. Medium was removed 
at 1 h or 24 h and wells were washed with PBS followed by the addition of 0.5 ml 
of 1% (v/v) solution of crystal violet reagent (Becton Dickinson) in PBS, and 
incubation at room temperature for 30 minutes. Biomass staining was solubilized 
with 0.5 ml of ethanol and spectrophotometric readings were recorded at O.D. 600 
nm for each sample at each time point. Statistical analysis is reported based on 
three independent experimental repeats (n = 3 ± SD) with triplicate technical 
replicates in each experiment. Statistical significance was denoted as *P ≤ 0.05 
and **P ≤ 0.001. 
 
Adherence inhibition studies. For inhibition of biofilm formation both synthetic C-
C’ loop peptide and IST-9 mAb were used. GAS WT and mutant strains were 
grown to logarithmic phase and pre-incubated with 1 mM synthetic C-C’ loop or 
scrambled peptide. 0.5 ml of the mixture was then added to ECM-treated wells in 
triplicate and incubated at 37oC in an atmosphere of 5% CO2–20% O2. 
Adherence inhibition at 1 h was analyzed spectrophotometrically following crystal 
violet staining. For antibody inhibition assay, ECM-treated wells were pre-
incubated with mAb IST-9 (10 g) for 1 h at room temperature. Wells were then 
washed with PBS to remove unbound antibody. 0.5 ml of logarithmic phase GAS 
wild-type and mutant strains were added to triplicate wells and incubated at 37 
oC in an atmosphere of 5% CO2–20% O2. Bacterial biomass was measured 
spectrophotometrically after 1 h following crystal violet staining. . Statistical 
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analysis is reported based on three independent experimental repeats (n = 3 ± 
SD) with triplicate technical replicates in each experiment. Statistical significance 
was denoted as *P ≤ 0.05 and **P ≤ 0.001. 
 
Microscopy Techniques  
Confocal Laser Scanning Microscopy (CLSM). To visualize GAS cells by CLSM, 
GAS wild-type and scl1-inactivated mutants were transformed with plasmid 
pSB027 (13, 20, 60) to express green fluorescent protein (GFP). GAS cells 
grown to O.D. 600 nm ~0.5 were inoculated onto untreated or cFn-coated 15-mm 
glass cover slips placed into 24-well tissue culture plate wells and incubated for 
24 h. Biofilms were washed gently with PBS and fixed with 3% paraformaldehyde 
in PBS at room temperature for at least 2 h. Cover slips were mounted to slides 
using Prolong Gold (Invitrogen). Fluorescent images were acquired using the 
confocal microscope (LSM 510 Carl Zeiss) equipped with a 63x/1.40 Oil Plan-
Apochromatic objective. Z-stack profiles were further deconvoluted stepwise by 
AutoQuant software at 0.36 m and were visualized as 3-dimensional images 
using NIS – Elements software. Additional visualization was performed using the 
Zeiss trinocular EPI fluorescence microscope equipped with four achromatic 
objectives. The Zeiss AxioCam Mrc5 camera and Zeiss AxioVision 4.8 software 
was used for image acquisition. 
Field Emission Scanning Electron Microscopy (FESEM). GAS biofilm samples 
were prepared and fixed as above. The samples were post-fixed in osmium 
tetroxide, dehydrated in an ethanol series, and dried using hexamethyldisalizane. 
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Samples were mounted onto aluminum stubs, sputter-coated with 
gold/palladium, and imaged on a Hitachi S-4800 field emission scanning electron 
microscope as previously reported (60). 
 
Cell culture techniques  
Fibroblast-derived extracellular matrix (fdECM) production and analysis. Adult 
human dermal fibroblasts (HDFa) were grown in Medium 106 (Invitrogen) 
supplemented with low serum growth supplement to confluency at 37oC in an 
atmosphere of 5% CO2. For fdECM production, HDFa were grown on sterile 15-
mm glass cover slips inserted into wells. Cells were removed by treatment with 2 
mM ethylene glycol tetraacetic acid, leaving naturally deposited network of 
extracellular matrix. Samples were washed gently with PBS and fixed with 3% 
paraformaldehyde for at least 2 h or overnight, and analyzed microscopically 
following Ponceau S staining or by FESEM. ELISA was performed to determine 
the presence of extracellular matrix components: total cellular fibronectin, EDA-
containing cFn, collagens type I, II, and IV, and laminin. Components present 
were detected with specific primary antibodies: anti-Fn (Sigma),anti-EDA/cFN 
(IST-9: Santa Cruz Biotechnology) anti-collagens I, II, IV (Chemicon/Millipore), 
and anti-laminin (Sigma). Appropriate secondary antibodies conjugated to 





Statistical analysis   
Statistical analysis was performed using the two-tailed paired Student’s t-test and 
significance was denoted at a level of *P ≤ 0.05 or **P ≤ 0.001. Error bars 
represent standard deviations with analyses based on three independent 
experimental repeats (n=3), each performed in triplicate technical replicates.  
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Figure 1. The EDA-domain mediates Scl1 binding to cellular fibronectin.  
(A) Schematic representation of cellular fibronectin (cFn). cFn monomer depicts 
type I, II and III repeats. The locations of the extra domain A (EDA) and type III 
repeat 4 are indicated, as sources for recombinant molecules rEDA and rIII4 
used. (B) Binding of ECM ligands to recombinant Scl (rScl) proteins. cFn-binding 
positive recombinant Scl1 (rScl) proteins P144 (rScl1.1), P161 (rScl1.28), and 
P176 (rScl1.41), as well as cFn-binding negative control protein P163 (rScl2.28) 
were immobilized onto Strep-Tactin-coated wells and incubated with cFn or cFn-
derived rEDA and rIII4 polypeptides. rScl-bound ligands were detected by ELISA 
with ligand-specific primary antibodies and appropriate HRP-conjugated 
secondary antibodies. Graphic bars indicate the mean OD415nm normalized 
against BSA controls. Statistical analysis was computer from three independent 
experimental repeats, each performed in triplicate wells (n = 3 ± SD).                  
(C) Characterization of binding specificity between rScl proteins and ECM 
ligands. Immobilized rScl1 proteins, P144, P161, and P176, were incubated with 
increasing concentrations (0.02 – 4.0 M) of cFn, rEDA and rIII4. Mean OD415nm, 





























Figure 2. Scl1-cFn interaction is mediated by the C-C’ loop region of EDA.  
Scl1–cFn interaction is mediated by the C-C’ loop region of EDA. The Scl1 
binding site within the EDA domain of cFn was mapped using peptide and 
antibody inhibition  ELISAs. For both assays, recombinant cFn-binding positive 
proteins P144 (rScl1.1), P161 (rScl1.28) and P176 (rScl1.41) were immobilized 
onto Strep-Tactin-coated wells. Following incubation with peptide or mAb bound 
ECM ligands were detected with specific primary antibodies and the 
corresponding HRP-conjugated secondary antibodies. Graphic bars indicate the 
mean OD415nm normalized against BSA controls. Statistical analysis was 
computed from three independent experimental repeats, each performed in 
triplicate wells (n = 3 ± SD). Statistical significance evaluates differences in ligand 
binding between untreated and treated samples at the levels of *P ≤ 0.05, **P ≤ 
0.001. (A) Structural representation of EDA. Ribbon model shows a b-sandwich 
composed of four b-strands, C, C‘, F and G, and the underlying three b-strands 
A, B and E (adapted from Shinde et al., 2008). The stick representation of the C-
C’ loop is shown and its 11-amino-acid sequence is indicated. The adjacent key 
residues involved in 91-integrin binding (D41 and G42) and for the mAb IST-9 
epitope (I43 and H44) are underlined. (B) Peptide inhibition assay. Immobilized 
rScl1 proteins were pre-incubated with increasing concentrations (0.0–1.0 mM) of 
the synthetic C-C’ loop peptide or the corresponding scrambled peptide, followed 
by the incubation with 0.25 M ECM ligands, cFn and rEDA. ECM ligand binding 
to rScl1 is shown. (C) Antibody blocking assay. ECM ligands (0.25 M) were pre-
incubated with increasing concentrations (0.0–10 g) of mAb IST-9. Mixtures 




















Figure 3. Scl1-EDA interaction represents a common, cFn-binding 
mechanism among epidemiologically diverse GAS strains. 
Scl1–EDA interaction represents a common, cFn-binding mechanism among 
epidemiologically diverse GAS strains. Eleven rScl proteins derived from diverse 
GAS strains of various M types were tested for rEDA and cFn binding. rScl 
proteins tested included the cFn-binding positive rScl1 proteins P144 (rScl1.1), 
P161 (rScl1.28), P186 (rScl1.12), P190 (rScl1.2), P217 (rScl1.52) and P176 
(rScl1.41), as well as cFn-binding negative rScl1 proteins P179 (rScl1.6) and 
P216 (rScl1.55), and rScl2 proteins P163 (rScl2.28), P177 (rScl2.4) and P178 
(rScl2.77). rScl proteins were immobilized onto Strep-Tactin-coated wells and 
incubated with ECM ligands pFn, cFn and rEDA. rScl-bound ECM ligands were 
detected by ELISA with ligand-specific primary antibodies and the appropriate 
HRP-conjugated secondary antibodies. Graphic bars indicate the mean OD415nm 
normalized against BSA controls. Statistical analysis was computed from three 
independent experimental repeats, each performed in triplicate wells (n = 3 ± 
SD). (A) Identification of rScl1–ECM ligand binding. Immobilized rScl proteins 
were incubated with 1 g per well of each ECM ligand. Designation of each rScl1 
or rScl2 construct, as well as the GAS M type from which each construct was 
derived, is indicated. (B) Peptide inhibition assay. Immobilized rScl proteins were 
pre-incubated with a 1.0 mM concentration of the synthetic C-C’ loop peptide or 
scrambled peptide and then with 1 g of each cFn or rEDA ligand. (C) Antibody 
blocking assay. ECM ligands cFn and rEDA (1 g) were pre-incubated with 10 g 



















Figure 4. Scl1-cFn binding mediates and enhances biofilm formation by 
GAS.  
WT GAS strains M41-, M28- and M1-type, their scl1-inactivated isogenic mutants 
(M41scl1, M28scl1, M1scl1), and the M41scl1-C mutant strain complemented in-
trans for Scl1.41 expression were compared for biofilm formation. (A) Biofilm 
formation on abiotic or cFn-coated surface. Biofilm formation for each GAS strain 
was evaluated spectrophotometrically following crystal violet staining. Graphic 
bars indicate the mean OD600 nm normalized against BSA controls. Statistical 
analysis was computed from three independent experimental repeats, each 
performed in triplicate wells (n = 3 ± SD); *P ≤ 0.05, **P ≤ 0.001. (B) Analysis of 
biofilms formed on cFn-coated surface using confocal laser scanning 
microscopy. GAS strains were transformed with the GFP-encoding plasmid and 
grown on cFn-coated glass coverslips for 24 h. Two-dimensional orthogonal 
views of GAS biofilms are representative of Z-stacks from 10 fields within a 
single experiment. Average vertical thickness is indicated in micrometers. 
Conversion to three-dimensional images was performed with conventional Z-
stacks, deconvoluted stepwise using AutoQuant, and transformed using NIS-
element software. Nick marks represent 5 mm in thickness and averages were 
























Figure 5. Scl1 binding to ECM derived from human dermal fibroblasts (HDFa) 
mediates and enhances biofilm formation by GAS. Adult normal HDFa were 
grown to confluency, detached by EGTA treatment and removed from the wells. 
GAS adherence to fibroblast-deposited ECM (fdECM) was analyzed using field 
emission scanning electron microscopy (FESEM) and overall biofilm formation on 
fdECM and cFn were compared spectrophotometrically following crystal violet 
staining. (A) Adherence of WT GAS to fdECM by FESEM. GAS strains were 
grown for 2 h on HDFa-deposited fdECM to analyze the early adherence stage in 
biofilm formation. FESEM images were taken with increasing magnification (left 
to right). Scale bars are indicated in micrometers. Row (i): images depict acellular 
fibrous network of deposited fibroblast-derived matrices. Rows (ii–iv): adherence 
of M1- (ii), M28- (iii) and M41-type (iv) GAS strains to deposited fdECM is 
observed. (B) fdECM supports Scl1-mediated GAS biofilm formation. WT M41-, 
M28- and M1-type GAS strains and their scl1-inactivated isogenic mutants were 
tested for initial adherence (1 h) and mature biofilm (24 h) in wells primed with 
either fdECM or with commercial cFn. Graphic bars indicate the mean OD600nm 
normalized against BSA controls. Statistical analysis was computed from three 
independent experimental repeats, each performed in triplicate wells (n = 3 ± 




















































Figure. 6. Inhibition of GAS adhesion by targeting the C-C’ loop of EDA. 
Spectrophotometric analysis following crystal violet staining at 1 h is shown. 
Black solid horizontal lines over-imposed on bars showing untreated samples of 
GAS WT strains represent adhesion values of the corresponding untreated scl1-
inactivated mutant strains (shown in Fig. S2). Absorbance values (OD600nm) 
reported are averages of at least two experiments done in triplicate wells. 
Percentage values each were compiled and shown below the graph. Statistical 
significance is denoted as *P ≤ 0.05 and **P ≤ 0.001. (A) Inhibition of GAS 
adhesion with synthetic C-C’ loop peptide. M1-, M28-, and M41-WT GAS strains 
were pre-treated with the exogenous C-C’ loop peptide or a scrambled loop 
peptide (not shown) and then added to ECM-coated wells. (B) Inhibition of GAS 
adhesion by mAb IST-9. ECM-coated wells were pre-treated with mAb IST-9 
followed by the addition of GAS strains. Below the graph, we present % 
adherence inhibition, resulting from genetic inactivation of their corresponding 

























Figure 7. A model of Scl1-mediated wound colonization by GAS. (Upper 
schematic) Initiation of GAS infection requires a skin infringement or portal of 
entry. During tissue repair, host cells deposit in the wound bed a provisional ECM 
matrix, which includes the EDA-enriched cFn to provide scaffolding for cell 
migration and proliferation through integrin binding, and functions to promote the 
wound healing process. (Lower schematic) GAS utilizes the Scl1 protein for 
targeted binding to the EDA domain of cFn. This Scl1 binding to EDA/cFn variant 
promotes GAS attachment and colonization of the wound in concert with other 
GAS adhesins that bind the N-terminal region of Fn. KC, keratinocytes; proECM, 



























Figure S1. Characterization of fibroblast-derived extracellular matrix (fdECM). 
Adult human dermal fibroblasts (HDFa) were grown in Medium 106 to 
confluency, detached from the underlying fdECM by EGTA treatment, and 
removed from the wells. (A) Ponceau S staining shows a complex fibrillar 
network of fdECM deposited by HDFa cells. (B) Composition of fdECM network. 
fdECM deposited in wells was evaluated for the presence of cFn, EDA/cFn, 
collagen type I, II, and IV, and laminin (shown from left to right respectively) by 
ELISA using specific primary antibodies and secondary HRP-conjugated 
antibody. Statistical analysis was computed from three independent experimental 
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Figure S2. Adhesion inhibition of GAS scl1 mutants by targeting the C-C’ loop of 
EDA. Spectrophotometric analysis following crystal violet staining at 1 h is 
shown. Graphic bars indicate the mean O.D.600nm normalized against BSA 
controls. Statistical analysis was computed from three independent experimental 
repeats, each performed in triplicate wells (n = 3 ± SD). Result: No statistically 
significant decrease in binding to any ECM by the GAS scl1-inactivated mutants 
was observed. No strains were inhibited with the treatment of the scrambled 
peptide (data not shown).  (A) Inhibition of GAS adhesion by C-C’ loop peptide. 
M1 scl1, M28 scl1, and M41 scl1 mutant strains were treated with synthetic C-C’ 
loop peptide or a scrambled loop peptide (not shown) and added to ECM-coated 
wells. (B) Inhibition of GAS adhesion by mAb IST-9. ECM-coated wells were pre-
treated with mAb IST-9 followed by the addition of GAS Scl1-negative mutant 
strains. Result: No statistically significant decrease in binding to any ECM by the 






























Group A Streptococcus is a globally disseminated, specialized human 
pathogen possessing numerous pathogenicity factors, including the Scl1 protein. 
Current work identified a novel mechanism by which GAS utilizes the Scl1 
protein to target an extra domain A (EDA)-containing spliced variant of cellular 
fibronectin (cFn) (Chapter 2 & 4) that enhances biofilm formation (Chapter 3) in 
vitro. Because expression and deposition of EDA/cFn in the wound plays an 
essential role in cicatrisation, the acquisition of the selective EDA/cFn binding by 
GAS, mediated by surface-attached Scl1, suggests a potential mechanism to 
abrogate the healing process allowing GAS to stably colonize tissue at the portal 
of entry and to establish biofilm within infected tissue. The implications of this 
mechanism rely on the importance of cFn in tissue repair and the impediment 
that infecting GAS strains may cause to this process. Therefore, the proposed 
Scl1-mediated wound colonization model (Chapter 4, Figure 7) will be outlined in 









Initiation of the Wound Healing Process. The dynamics of tissue repair and 
regeneration are complex and reliant upon the cellular interaction with the 
extracellular matrix (ECM). The ECM is comprised of numerous macromolecules 
including collagens, fibronectins, laminins, elastin, and proteoglycans, each 
having a specific biological function. Specifically, the fibronectins, pFn and cFn, 
make up a large heterogeneous group of glycoproteins that have been intensely 
studied and characterized. cFn is predominantly produced by macrophages, 
human dermal fibroblasts, and myofibroblasts that are distributed within the 
dermis and basement membrane of the dermis-epidermis interface. cFn has 
varying functions but is critically important during vertebrate development and, 
most relevant to the current research, in wound healing. Following skin 
infringement (Figure 1 A), pFn is deposited within the injured site and along with 
fibrin and provides an initial soluble extracellular matrix. This matrix provides a 
base for cell migration and will function as a template for the future mature ECM. 
Recruited platelets release cytokines inducing an inflammatory response with 
macrophages and neutrophils entering the wound area. In a short time, 
granulation tissue is constructed as fibroblasts begin secreting collagen and 
EDA/cFn in the wounded site to produce an insoluble, provisional matrix 
(proECM). cFn orchestrates integrin ligation, organization of the new granulation 
tissue, and restructuring of the ECM to restore a stable, scaffold for cellular 
regeneration (28, 34, 70, 87, 98, 121, 129). Simultaneously, keratinocytes (Kn) 
begin to migrate towards and over the wounded site secreting laminin that 
interacts with integrins on the surrounding cells and form a dermoepidermal 
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basement membrane forming a new epithelial layer. Kn cells also produce matrix 
metalloproteinases (MMPs), specifically MMP-1, that degrade unneeded native 
collagens to clear the wound (28, 67, 114). Finally, contraction of the wound is 
initiated by myofibroblasts bridging the surrounding collagen and cFn with 
adjacent cells. During this process, cFn is critical for rebuilding of ECM and its 
biological importance is suggestive as to the reason why many microorganisms, 




Scl1-Mediated GAS Colonization of Wounded Tissue. It is suggested that 
microbial colonization occurs in all cutaneous and chronic wounds, regardless of 
whether wounds are infected endogenously or exogenously. Common features of 
the cutaneous acute and chronic wounds are inflammation, and disruption and 
destruction of the tissue. However, in case of chronic infections, the lack of 
progression in the wound healing process and lack of response to treatment 
occur and are associated with biofilm formation (36). Staphylococcus aureus and 
GAS are among the most commonly found in acute, subcutaneous and 
cutaneous wounds, as well as in chronic wounds (103). It has been 
demonstrated that  infection of the wound with S. aureus causes a disruption of 
the normal regeneration of tissue (104). The loss of skin integrity can be caused 
by insect bites, cuts, burns, ulcers, dermatitis, surgeries or found in regions of on-
going infection. The temperature and pH of the skin, as well as, poor hygiene 
also contribute to tissue integrity. Sustainment of resident or transient flora 
colonization within the wounded tissue depends on immunological, microbial, and 
environmental factors (123). The introduction of GAS into a skin infringement has 
the potential to develop into acute or chronic infections based on the virulent 
nature of the strain and its capacity to adhere to host cells and establish 
colonization. With GAS’s entrance into a wound site, the bacterium will utilize an 
array of surface adhesins expressed by a given strain, such as the Fn-binding 
proteins, referenced in Chapter 1, to cooperatively interact with host cellular and 
extracellular components. We have previously reported that the Scl1 protein of 
M41-type GAS interacts with the collagen-binding integrins, 21 and 111, via a 
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GLPGER sequence motif located within the CL region of Scl1. It was further 
shown that Scl1-integrin binding facilitates GAS adherence and internalization 
into human epithelial and endothelial cells, which also results in an enhanced 
pathogen survival and re-emergence from these cells (11, 12, 46). This is 
representative of one Scl1-mediated mechanism for GAS to initiate colonization. 
Investigations presented here identified targeted binding mediated by the V 
region of Scl1 to selected human ECM components, cFn and Lm, thus, providing 
a second mechanism of adherence and demonstrating a dichotomy of ligand 
binding by Scl1 proteins (Chapter 2) (81). The significance of the Scl1-cFn 
interaction characterized in our early work, subsequently led to a discovery of a 
new GAS-cFn-binding mechanism, which is mediated by the extra domain A 
(EDA) of cFn (Chapter 4), with intriguing potential consequences to wound 
healing.  
Although cFn  is transcribed from a single gene, there are up to twenty 
isoforms identified in human tissues that are generated by tissue-specific 
alternative splicing of the mRNA transcript occurring among the type III repeats 
(44). cFn contains extra domains EDA and EDB, not found in pFn (Chapter 4, 
Figure 1), and has more than a dozen binding sites that recognize and bind 
important biological molecules and integrins, many of which bind the common 
RGD motif (65, 87, 121). However, the EDA domain binds additional integrins 
that are different from the RGD-recognizing integrins (129). Structurally, the EDA 
domain is homologous to the type III repeats. Located between type III11 and 
III12, it forms a -strand sandwich composed of two -sheets containing four -
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strands, C-C’, F-G, with three underlying -strands A-B, and E (30, 60, 61). 
Expression of this domain is critical during periods of embryogenesis and 
organogenesis. In non-diseased conditions, expression of EDA is down-
regulated and maintained at low levels (< 1% total Fn in the body) (91); however, 
during certain pathological states and specifically in wound healing, EDA 
expression is significantly up-regulated. Functionally, it mediates interactions with 
41,91, and  integrins (131) to induce fibroblast differentiation (56, 107) 
and also contributes considerably to accelerate kerotinocyte migration during 
wound healing (33, 35, 108). The EDA-integrin interaction is mediated by an 
eleven amino-acid loop sequence (TYSSPEDGIHE) located between the C and 
C’ -strands with the D-G being the targeted amino acids. In general, the binding 
of cFn to a ligand often results in conformational changes exposing “cryptic” 
binding sites or sites that are not readily accessible until the structure of the 
molecule is stretched or bent. The C-C’ loop region of EDA is characterized as 
one of these sites. Several integrin-blocking monoclonal antibodies 
encompassing the C-C’ loop region of EDA, such as mAb IST-9, were generated 
that inhibited the 4- and 9-integrin-mediated cell adhesion (60, 61). Here, in a 
series of ELISA-based studies, it was identified that rScl1 proteins derived from 
M41-, M28- and M1-type GAS bound recombinant EDA (rEDA) and that binding 
could be blocked more than 50% by pre-treatment of rEDA with the mAb IST-9 or 
by pre-treatment of rScl1 proteins with the synthetic C-C’ loop sequence. If this in 
vitro observed activity of rScl1 functions in vivo during GAS infection, cell-surface 
Scl1 could compete with integrins for EDA/cFN binding abrogating human cell 
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migration and adhesion, thus, impairing wound healing. As shown in Figure 1 B, 
implications of this data suggest that Scl1-EDA binding may affect several other 
cell types that express 91 integrin, and participate in wound healing and 
inflammation, including epidermal keratinocytes (108, 109), as well as 
neutrophils, epithelial and muscle cells (84, 119). This hypothesis, however, has 
yet to be verified experimentally.  
In the later stages of wound healing and in preparation of the wound bed 
for tissue regeneration, matrix metalloproteinases are often present. MMPs, such 
as MMP-1, also known as interstitial collagenase and fibroblast collagenase, 
degrades unneeded native collagens, specifically collagens type I and III. MMPs 
target open-state regions in the collagen triple-helix that lie adjacent to the MMP 
cleavage site (77, 102). Due to the structural mimicry of Scl1 to collagen, it has 
been questioned if human MMPs will cleavage the CL region of Scl proteins thus, 
eliminating the Scl1-cFn interaction. Yu and coworkers engineered chimeric rScl 
proteins containing fragments of the human collagen type III embedded within 
the CL-region of a rScl2 protein (135). They reported that the original CL domain 
of rScl2 was not cleaved by either MMP-1 or MMP-13, whereas both efficiently 
degrade triple-helical mammalian collagens. Insertion of a minimum of 5 GXY 
triplets, encompassing the original MMP recognition and cleavage site, made the 
chimeric rScl2-huCol III protein sensitive to MMP cleavage. It will be important to 
test if GAS secreted proteases, such as SpeB, and or collagenases cleave Scl1 
proteins at the cell surface, thus, eliminating the heterophilic Scl1-cFn interaction 
as well as the hemophilic Scl1-Scl1 interactions. Our earlier work showed that 
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the collagen triple helices of various rScl constructs thermally unfold above 
normal human core-body temperature of 37oC (40, 128), whereas they are stable 
at a human skin temperature ~34oC. These two phenomena e.g., Scl1 
proteolysis and thermal unfolding may have important biological consequences 
for GAS wound colonization via ECM binding, for a subsequent tissue 
microcolony formation, and for a successful infection of the human host. This line 





























Scl1-Mediated GAS Biofilm Formation within Wounded Tissue. Bacterial 
biofilms are well-documented among both acute and chronic infections (103). 
Biofilms denote a serious clinical problem and are present in up to 65% of human 
bacterial infections (92). By broad definition, biofilm is an aggregation of surface-
associated, or sessile, microorganisms often encased within an extracellular 
polymeric substance also called glycocalyx (50, 103), which contains complex 
biological material containing polysaccharides, DNA, proteins, and lipids with 
“crypts” or water channels for nutrient flow (22, 25). Populations of microbes 
within a biofilm have an altered genotype and may undergo multiple phenotypic 
switches such as altered polysaccharide profiles and adhesin expression, as well 
as morphological changes as compared to their planktonic counterparts (15, 73, 
113). Biofilm establishment within wounds provide numerous advantages for 
organisms in survival, including an increase in antimicrobial resistance up to a 
thousand-fold (32), as well as a decreased sensitivity to immunological and 
chemical assault. Studies of the structural and physiological features of various 
biofilm models support the hypothesis that bacterial biofilms play an important 
role in wound colonization, infection, and abrogation of wound healing (27, 38, 
76, 79, 80, 89, 90, 125). 
Over the course of the last decade, research on GAS  has shown a strain-
to-strain variation for the capacity of biofilm formation (59, 81). GAS biofilm was 
first reported in human clinical skin specimens in the form of tissue microcolonies 
encased in a glycocalyx (1). GAS biofilm was also associated with previously 
unreported penicillin sensitivity and possible antibiotic treatment failure (18). 
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Gene expression of sessile GAS cells associated with biofilm differ from their 
planktonic form; for example, the Scl1 expression was upregulated during initial 
stages, whereas the streptococcal cysteine protease, SpeB, was over-expressed 
within mature biofilm (15, 101). Studies employing GAS isogenic mutants with 
altered surface components, including proteins, pili, capsule and lipoteichoic 
acid, as well as mutants in regulatory genes and wide-spectrum secreted 
protease had significant impact on biofilm phenotype (20, 26, 54, 66).  
An initial step in GAS colonization of a wounded site is often mediated by 
surface adhesins. As proposed in our Scl1-mediated biofilm model (Figure 2), 
planktonic GAS cells utilize the Scl1 protein to secure attachment to EDA-
containing cFn expressed by wounded cells at a site of skin injury and initiate 
host colonization. As colonization progresses, sessile GAS cells proliferate 
producing swells of microcolonies within the infected area. Over time, these 
microcolonies develop into macrocommunities that may remain intact forming an 
immune- and antimicrobial-resistant biofilm. Biofilm dispersal and bacterial 
dissemination may be induced by environmental factors such as elevated body 
temperature or loss of nutrients, as well as the production of bacterial proteases 
such as SpeB directly altering the structural stability of protein-protein 
interactions. Loosely-associated small microcolonies or even chains of GAS will 
eventually filter into adjacent tissues to colonize another niche ultimately 
repeating the process.  
This body of work directly addresses the initial adherence stage of GAS 
biofilm formation and supports our proposed model. With the identification of the 
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Scl1-EDA/cFn interaction, we proposed that this binding greatly or significantly 
enhances GAS biofilm formation via a bridging mechanism to host cells. To 
address this hypothesis, we investigated three epidemiologically different GAS 
strains for their capacity to form biofilm on untreated or ECM-deposited surfaces: 
M41, M1, and M28. The M41-type GAS strain was used as a representative 
strain, which has been historically associated with non-invasive skin infections. 
During the 1950s-60s, outbreaks of impetigo and other superficial infections 
occurred in regions of the United States (Minnesota and Alabama) as well as the 
island nation, Trinidad. These infections were linked to acute glomerulonephritis, 
a rare kidney infection sometimes occurring after streptococcal infections (2, 23, 
24, 124). For comparison, M1-type GAS, a highly invasive strain and the most 
commonly isolated from suppurative infections, and M28-type GAS, a strain 
historically over-represented in puerperal sepsis cases as well as invasive 
infections, were used. We demonstrate using a conventional crystal violet 
staining assay that these strains have varying capacity to form biofilm on 
untreated (plastic) surfaces with the M41-type producing a more robust biofilm as 
compared to M1 and M28. This observation was confirmed visually by 
microscopy and revealed distinct variations in cell-surface morphology and 
microcolony architecture for each strain. In assessment of wild-type strains and 
their scl1-inactivated isogenic mutants in biofilm formation, we observed a 
significant decrease in biofilm capacity for all mutant strains indicating an 
important role for the Scl1 protein in this process. Directly supporting our model, 
we observed increased biofilm formation when GAS strains were grown on ECM-
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deposited surfaces (cFn, rEDA, or fdECM) as compared to those grown on 
plastic (Chapter 3). Thus, these studies reveal a novel mechanism that can be 
implemented by GAS during the initial stages of colonization within a skin wound 
that significantly increases the probability of stabile adherence to host cells 
facilitating the potential for biofilm formation. 
Concluding Remarks. In GAS pathogenesis, the Scl1 protein has been 
conclusively established as an important, multifunctional surface adhesin. Being 
ubiquitously expressed by GAS strains and participating in the binding of 
biologically significant molecules such as cellular fibronectin, it is an 
indispensable virulence factor for host colonization among pathogenically diverse 
strains. With research ongoing to further dissect molecular mechanisms 
mediated by GAS surface components, this work provides substantial support 
toward this effort and for future efforts to continue the characterization of the 







































Figure 1. Step-by-step model of wound healing and role of Scl1 in host 
colonization. 
 
A. Wound formation and initiation of healing process. A skin infringement 
occurs. Plasma fibronectin (pFn) and fibrin are deposited within the wounded site 
and recruit platelets to form a clot. Platelets induce an inflammatory response by 
recruiting macrophages and neutrophils (PMNs) to the area, which begin to 
engulf and degrade necrotic cells and unneeded ECM components. Dermal 
fibroblasts (DF) begin secreting collagens and EDA-containing cellular fibronectin 
(EDA/cFn) into the site to compose a provisional ECM (proECM) that will be used 
as a scaffold for newly constructed ECM. Keratinocytes begin to proliferate and 
migrate toward and over the wound forming a monolayer to secure the site. 
 
B. Scl1-mediated wound colonization by GAS. (Upper schematic) Initiation of 
GAS infection requires a skin infringement or portal of entry. (Bottom schematic; 
NT and KC cells are not shown according to their location in the wound) During 
tissue repair, multiple cells deposit in the wound bed a provisional ECM matrix, 
which includes the EDA-enriched cFn to provide scaffolding for cell migration and 
proliferation through the binding of  integrin, and functions to promote the 
wound healing process. GAS utilizes the Scl1 protein for targeted binding to the 
EDA domain of cFn, thus, competing with -mediated binding of the 
inflammatory and epithelial cells. This competitive Scl1-EDA binding directly 
promotes GAS attachment and colonization of the wound which also may 
delaying the healing process allowing increased time to establish infection. KC, 
(keratinocytes); proECM (provisional extracellular matrix); DF, (dermal 
fibroblasts); NT, (neutrophils). 
 
C. Scl1-mediated biofilm formation in wounded tissue. Microcolonies of GAS 
proliferate in the wounded site, stabilize their adherence to surrounding host cells 
via the Scl1-EDA/cFn “bridging” mechanism, and develop into a large 
microcommunity resistant to penetration of host immunity or antimicrobial attack. 
Individual GAS cells, chains or small microcolonies loosely associated with the 
community will disseminate into the tissue, adhering to surrounding host cells or 








Figure 4. Scl1-mediated GAS biofilm formation model. Stage 1 of GAS 
biofilm formation is often a protein-protein mediated interaction to initiate binding 
to a substratum. Scl1 expressed by planktonic GAS cells binds extracellular 
matrix (ECM) components as a “bridging” mechanism to adhere to host cells. In 
stage 2, microcolonies or “aggregates of cells” form and are stabilized by 
interacting with the surrounding host cells and ECM components, which may be 
cooperative with Scl1-Scl1 dimerization. The microcolonies proliferate producing 
a mature biofilm or “macrocommunity” that is often resistance to host immune 
defenses as well as environmental attacks. In stage 3, biofilm disruption occurs, 
which may be induced through proteolytic activities of secreted GAS proteases, 
nutrient deprivation, or other altered environmental conditions. Dissemination or 
dispersal of individual GAS cells, chains of cells, or loosely-associated 
microcolonies into adjacent tissues initiate the biofilm formation process again in 
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